Claus Goerg Roehrborn

Claus Goerg Roehrborn's AcademicInfluence.com Rankings

Philosophy

#3583

World Rank

#5757

Historical Rank

Logic

#1254

World Rank

#1955

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Claus Goerg Roehrborn's Degrees

Doctorate Medicine University of Hamburg

Why Is Claus Goerg Roehrborn Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Claus Goerg Roehrborn's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. (2003) (1790)
Radical prostatectomy versus observation for localized prostate cancer. (2012) (1359)
Update on AUA guideline on the management of benign prostatic hyperplasia. (2011) (1018)
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. (2007) (868)
The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia (1998) (863)
Benign prostatic hyperplasia. (2020) (717)
Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. (2002) (690)
Female Stress Urinary Incontinence Clinical Guidelines Panel summary report on surgical management of female stress urinary incontinence. The American Urological Association. (1997) (657)
The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. (2010) (651)
Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. (1998) (643)
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. (2004) (516)
Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. (1996) (468)
Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. (2006) (421)
Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. (2003) (413)
The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. (2008) (395)
A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. (2006) (379)
The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. (1998) (375)
Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. (2003) (366)
Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. (1999) (349)
The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. (2008) (325)
Benign prostatic hyperplasia: an overview. (2005) (323)
Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. (2008) (291)
Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. (1999) (286)
A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. (2012) (276)
Benign Prostatic Hyperplasia: Diagnosis and Treatment (1998) (269)
Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. (2004) (265)
Cost comparison of robotic, laparoscopic, and open radical prostatectomy for prostate cancer. (2010) (261)
An updated catalog of prostate cancer predictive tools (2008) (260)
Optimal method of urgent decompression of the collecting system for obstruction and infection due to ureteral calculi. (1998) (260)
Proposed cutoff values to define bladder outlet obstruction in women. (1999) (256)
Tadalafil Relieves Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia (2007) (245)
A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer (2013) (244)
Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. (2011) (243)
α1-Adrenergic Receptors and Their Inhibitors in Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia (2004) (233)
Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2018) (231)
Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. (2006) (228)
Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action (2011) (225)
Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. (2000) (224)
The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. (1996) (220)
Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). (2011) (219)
Lower urinary tract symptoms revisited: a broader clinical perspective. (2008) (217)
Clinical guidelines panel on erectile dysfunction: summary report on the treatment of organic erectile dysfunction. The American Urological Association. (1996) (217)
Management of ureteral calculi: a cost comparison and decision making analysis. (2002) (212)
Efficacy and Safety of Long-Term Treatment with the Dual 5α-Reductase Inhibitor Dutasteride in Men with Symptomatic Benign Prostatic Hyperplasia (2004) (209)
Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. (1999) (207)
Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. (2007) (204)
Benign prostatic hyperplasia: a progressive disease of aging men. (2003) (202)
Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. (2007) (200)
Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis. (1999) (194)
BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF‐ONE (2008) (194)
Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. (2017) (189)
The economic burden of prostate cancer (2011) (183)
Survivin expression is associated with features of biologically aggressive prostate carcinoma (2004) (178)
The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. (2013) (172)
α1‐Adrenoceptor subtypes and lower urinary tract symptoms (2008) (166)
Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound. (1997) (164)
Evaluation and treatment of lower urinary tract symptoms in older men. (2009) (164)
Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. (2005) (162)
WATER: A Double‐Blind, Randomized, Controlled Trial of Aquablation® vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia (2018) (160)
Minimally Invasive Prostate Convective Water Vapor Energy Ablation: A Multicenter, Randomized, Controlled Study for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. (2016) (159)
Evaluation and treatment of lower urinary tract symptoms in older men. (2009) (158)
Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnoses and prostate specific antigen levels. (1996) (155)
Urinary retention and post-void residual urine in men: separating truth from tradition. (2008) (154)
A Cellular Anatomy of the Normal Adult Human Prostate and Prostatic Urethra (2018) (154)
An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. (2014) (151)
Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. (2001) (149)
Analysis of factors contributing to success or failure of 1-stage urethroplasty for urethral stricture disease. (1994) (148)
Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. (2011) (147)
Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. (2012) (143)
Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. (2004) (143)
Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. (2004) (142)
A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. (1998) (141)
Critical review of lasers in benign prostatic hyperplasia (BPH) (2011) (141)
The Progression of Benign Prostatic Hyperplasia: Examining the Evidence and Determining the Risk (2001) (141)
Caveolin‐1 overexpression is associated with aggressive prostate cancer recurrence (2007) (140)
Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. (2012) (138)
Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer (2008) (138)
Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. (2007) (138)
Rezūm Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: 4-Year Results From Randomized Controlled Study. (2019) (133)
Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative, international overview. (2001) (131)
Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. (2010) (131)
Using biopsy to detect prostate cancer. (2008) (129)
Updated meta‐analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia (2004) (129)
Assessment of basic endoscopic performance using a virtual reality simulator. (2002) (128)
Long-term consequences of castration in men: lessons from the Skoptzy and the eunuchs of the Chinese and Ottoman courts. (1999) (125)
Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation (2006) (124)
A multinational, multi-institutional study comparing positive surgical margin rates among 22393 open, laparoscopic, and robot-assisted radical prostatectomy patients. (2014) (124)
Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) (2011) (122)
The impact of intense laparoscopic skills training on the operative performance of urology residents. (2001) (122)
The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. (2009) (121)
Evidence-based validation of the predictive value of the American Association for the Surgery of Trauma kidney injury scale. (2007) (116)
Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. (2001) (116)
Microwave thermotherapy for benign prostatic hyperplasia with the Dornier Urowave: results of a randomized, double-blind, multicenter, sham-controlled trial. (1998) (114)
A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. (2009) (114)
Gleason Scores from Prostate Biopsies Obtained with 18-Gauge Biopsy Needles Poorly Predict Gleason Scores of Radical Prostatectomy Specimens (1998) (113)
Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy. (2004) (113)
Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. (2016) (113)
1277: The Impact of Acute or Chronic Inflammation in Baseline Biopsy on the Risk of Clinical Progression of BPH: Results from the MTOPS Study (2005) (112)
Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. (2006) (110)
A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. (2005) (109)
Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial. (2007) (109)
Definition of at‐risk patients: baseline variables (2006) (108)
Prospective randomized comparison of high energy transurethral microwave thermotherapy versus alpha-blocker treatment of patients with benign prostatic hyperplasia. (1999) (106)
The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study. (2009) (105)
Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. (1996) (105)
Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach. (2002) (105)
Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. (2005) (104)
Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. (2014) (104)
Factors influencing the outcomes of penile prosthesis surgery at a teaching institution. (2003) (101)
Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. (2004) (100)
Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4‐year results from the randomized, double‐blind Combination of Avodart and Tamsulosin (CombAT) trial (2011) (99)
Three year results of the prostatic urethral L.I.F.T. study. (2015) (98)
The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia. (2007) (97)
Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. (2013) (96)
Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. (2007) (96)
Questionnaire-based assessment of bladder dysfunction in patients with mild to moderate Parkinson's disease. (2000) (94)
Three-Year Outcomes of the Prospective, Randomized Controlled Rezūm System Study: Convective Radiofrequency Thermal Therapy for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. (2018) (92)
Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. (2006) (92)
Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. (2002) (91)
Nutraceuticals in Prostate Disease: The Urologist's Role. (2008) (90)
Treatment of LUTS secondary to BPH while preserving sexual function: randomized controlled study of prostatic urethral lift. (2014) (90)
A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia (2012) (89)
Virtual ureteroscopy predicts ureteroscopic proficiency of medical students on a cadaver. (2004) (88)
Efficacy and tolerability of tolterodine extended‐release in men with overactive bladder and urgency urinary incontinence (2006) (88)
Long-term patient survival after cystectomy for regional metastatic transitional cell carcinoma of the bladder. (1991) (88)
Improved Prediction of Disease Relapse after Radical Prostatectomy through a Panel of Preoperative Blood-Based Biomarkers (2008) (88)
Erectile and Ejaculatory Function Preserved With Convective Water Vapor Energy Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Randomized Controlled Study. (2016) (87)
Transurethral needle ablation for benign prostatic hyperplasia: 12-month results of a prospective, multicenter U.S. study. (1998) (85)
Reduction in hospital admission rates due to post-prostate biopsy infections after augmenting standard antibiotic prophylaxis. (2013) (83)
Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. (2008) (83)
Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. (2006) (83)
Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. (2006) (83)
Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia. (2000) (82)
The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. (2006) (80)
Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. (2007) (80)
Can transabdominal ultrasound estimation of postvoiding residual (PVR) replace catheterization? (1989) (80)
Accurate determination of prostate size via digital rectal examination and transrectal ultrasound. (1998) (80)
Variability of repeated serum prostate-specific antigen (PSA) measurements within less than 90 days in a well-defined patient population. (1996) (79)
Corrigendum to "The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4-Year Results from the CombAT Study" [Eur Urol 2010;57:123-31]. (2010) (79)
Urinary Retention in Patients with BPH Treated with Finasteride or Placebo over 4 Years (2000) (79)
Convective Thermal Therapy: Durable 2‐Year Results of Randomized Controlled and Prospective Crossover Studies for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (2017) (78)
Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. (2009) (78)
Combination Therapy With Doxazosin and Finasteride for Benign Prostatic Hyperplasia in Patients With Lower Urinary Tract Symptoms and a Baseline Total Prostate Volume of 25 Ml or Greater (2006) (77)
Does finasteride alter the pathology of the prostate and cancer grading? (2004) (77)
Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. (1999) (77)
Extended‐release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score (2008) (76)
Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment (2010) (75)
Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I, Initial Work-up and Medical Management. (2021) (74)
Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. (2004) (74)
Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. (2009) (74)
Antimicrobial prophylaxis prior to shock wave lithotripsy in patients with sterile urine before treatment: a meta-analysis and cost-effectiveness analysis. (1997) (73)
A patient‐derived explant (PDE) model of hormone‐dependent cancer (2018) (72)
Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men (2017) (72)
Add‐on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α‐blocker treatment for lower urinary tract symptoms (2012) (71)
Advanced transitional cell carcinoma of the upper urinary tract: patterns of failure, survival and impact of postoperative adjuvant radiotherapy. (1998) (71)
Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. (2008) (70)
Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design. (2007) (69)
Non-Cell-Autonomous Regulation of Prostate Epithelial Homeostasis by Androgen Receptor. (2016) (68)
Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Part II-Surgical Evaluation and Treatment. (2021) (68)
Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. (2010) (67)
The Role of Transabdominal Ultrasound in the Prostatic Hypertrophy (1986) (67)
External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy. (2008) (66)
The Benign Prostatic Hyperplasia Registry and Patient Survey: study design, methods and patient baseline characteristics (2007) (66)
Robot-Assisted Versus Open Simple Prostatectomy for Benign Prostatic Hyperplasia in Large Glands: A Propensity Score-Matched Comparison of Perioperative and Short-Term Outcomes. (2017) (66)
Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH (2010) (65)
Changes in amount and intracellular distribution of androgen receptor in human foreskin as a function of age. (1987) (65)
Emerging Minimally Invasive Treatment Options for Male Lower Urinary Tract Symptoms. (2017) (65)
MR Imaging-Transrectal US Fusion for Targeted Prostate Biopsies: Implications for Diagnosis and Clinical Management. (2015) (64)
Long-term followup of the North American multicenter UroLume trial for the treatment of external detrusor-sphincter dyssynergia. (1999) (64)
Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia. (2013) (63)
Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin. (2001) (63)
Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial. (2008) (63)
Erectile Dysfunction and Lower Urinary Tract Symptoms. (2017) (63)
3.5 cm artificial urinary sphincter cuff erosion occurs predominantly in irradiated patients. (2015) (62)
Long‐term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5α‐reductase inhibitor dutasteride: results of 4‐year studies (2005) (62)
Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia. (2006) (61)
The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4‐year data from the Combination of Avodart and Tamsulosin (CombAT) study (2011) (59)
Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction (2013) (59)
5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery. (2004) (59)
Effect of dutasteride, tamsulosin and the combination on patient‐reported quality of life and treatment satisfaction in men with moderate‐to‐severe benign prostatic hyperplasia: 2‐year data from the CombAT trial (2009) (59)
THE EFFECTS OF 5α-REDUCTASE INHIBITORS ON THE NATURAL HISTORY, DETECTION AND GRADING OF PROSTATE CANCER: CURRENT STATE OF KNOWLEDGE (2005) (58)
Convective radiofrequency water vapor thermal therapy for benign prostatic hyperplasia: a single office experience (2018) (58)
Interexaminer reliability and validity of a three-dimensional model to assess prostate volume by digital rectal examination. (2001) (58)
Embryological and diagnostic aspects of seminal vesicle cysts associated with upper urinary tract malformation. (1986) (57)
Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily (2008) (57)
Predictive Value of Plasma Hepatocyte Growth Factor/Scatter Factor Levels in Patients with Clinically Localized Prostate Cancer (2008) (56)
Do oral antimuscarinic drugs carry an increased risk of acute urinary retention? (2009) (56)
Salvage radiotherapy for biochemical failure of radical prostatectomy: a single-institution experience. (2003) (56)
Cost‐effectiveness of prostate cancer chemoprevention (2008) (55)
Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting. (1998) (55)
Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia. (2010) (55)
Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies. (2013) (55)
Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. (2001) (53)
Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2‐year placebo‐controlled study (2006) (53)
Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride. (2006) (52)
Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer. (2002) (52)
Development of a highly accurate nomogram for prediction of the need for exploration in patients with renal trauma. (2008) (52)
Chronic Prostate Inflammation is Associated with Severity and Progression of Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms and Risk of Acute Urinary Retention. (2016) (52)
Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4‐year results of the CombAT study (2014) (51)
Transurethral intravesical electrotherapy for neurogenic bladder dysfunction in children with myelodysplasia: a prospective, randomized clinical trial. (1992) (50)
The percent of biopsy cores positive for cancer is a predictor of advanced pathological stage and poor clinical outcomes in patients treated with radical prostatectomy. (2004) (50)
Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial. (2011) (50)
Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. (2002) (50)
Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. (2004) (50)
Features and outcomes of patients with grade IV renal injury (2006) (50)
Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial. (2011) (49)
Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry. (2011) (49)
WATER II (80–150 mL) procedural outcomes (2018) (48)
Distinguishing neurogenic from non-neurogenic detrusor overactivity: a urodynamic assessment of lower urinary tract symptoms in patients with and without Parkinson's disease. (2003) (48)
Three months’ treatment with the α1-blocker alfuzosin does not affect total or transition zone volume of the prostate (2006) (48)
Randomized Controlled Trial of Aquablation versus Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia: One-year Outcomes. (2019) (48)
The effects of transurethral needle ablation and resection of the prostate on pressure flow urodynamic parameters: analysis of the United States randomized study. (1999) (47)
Benign prostatic hyperplasia (2001) (47)
Serum Dioxin, Testosterone, and Subsequent Risk of Benign Prostatic Hyperplasia: A Prospective Cohort Study of Air Force Veterans (2006) (47)
Targeting phenotypic heterogeneity in benign prostatic hyperplasia. (2017) (46)
Predictive value of primary Gleason pattern 4 in patients with Gleason score 7 tumours treated with radical prostatectomy (2004) (46)
Decision analysis model comparing cost of multiparametric magnetic resonance imaging vs. repeat biopsy for detection of prostate cancer in men with prior negative findings on biopsy. (2015) (46)
Comparison of prostate cancer detection at 3-T MRI with and without an endorectal coil: A prospective, paired-patient study. (2016) (46)
The effect of the approach to radical prostatectomy on the profitability of hospitals and surgeons (2010) (46)
Preoperative Plasma Endoglin Levels Predict Biochemical Progression After Radical Prostatectomy (2008) (46)
Acute urinary retention: risks and management. (2005) (45)
The value of your time: evaluation of effects of changes in medicare reimbursement rates on the practice of urology. (2004) (45)
Neoadjuvant and adjuvant alpha-blockade improves early results of high-energy transurethral microwave thermotherapy for lower urinary tract symptoms of benign prostatic hyperplasia: a randomized, prospective clinical trial. (1999) (45)
Enlarged prostate: A landmark national survey of its prevalence and impact on US men and their partners (2006) (45)
The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study (2009) (44)
Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride. (2015) (44)
Relationship between prostate specific antigen and indexes of prostate volume in Japanese men. (2005) (44)
Efficacy of alpha-Adrenergic Receptor Blockers in the Treatment of Male Lower Urinary Tract Symptoms. (2009) (44)
Use of Preoperative Plasma Endoglin for Prediction of Lymph Node Metastasis in Patients with Clinically Localized Prostate Cancer (2008) (44)
The so-called "placebo effect" in benign prostatic hyperplasia treatment trials represents partially a conditional regression to the mean induced by censoring. (1998) (44)
Interexaminer reliability of transrectal ultrasound for estimating prostate volume. (2001) (43)
Removal of UroLume endoprosthesis: experience of the North American Study Group for detrusor-sphincter dyssynergia application. (2000) (43)
PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer. (2009) (43)
Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. (2001) (41)
The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response. (2007) (41)
Targeted transurethral microwave thermotherapy versus alpha-blockade in benign prostatic hyperplasia: outcomes at 18 months. (2001) (41)
Aquablation for Benign Prostatic Hyperplasia in Large Prostates (80-150 cc): 1-Year Results. (2019) (41)
Quantifying the impact of prostate volumes, number of biopsy cores and 5alpha-reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modeling. (2007) (40)
Long-term medical-care costs related to prostate cancer: estimates from linked SEER-Medicare data (2010) (40)
Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia. (2006) (40)
Do urological symptoms cluster among women? Results from the Boston Area Community Health Survey (2008) (40)
DISAPPOINTING INITIAL RESULTS WITH TRANSURETHRAL ALPROSTADIL FOR ERECTILE DYSFUNCTION IN A UROLOGY PRACTICE SETTING (1999) (39)
Three-year outcomes after Aquablation therapy compared to TURP: results from a blinded randomized trial. (2020) (39)
Have complication rates decreased after treatment for localized prostate cancer? (1999) (39)
Standing cystourethrogram: an outcome measure after anti-incontinence procedures and cystocele repair in women. (2001) (39)
Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of Rezūm Water Vapor Thermal Therapy for Treatment of Moderate-To-Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. (2021) (38)
Variation in institutional review board responses to a standard protocol for a multicenter randomized, controlled surgical trial. (2009) (38)
Two-Year Outcomes After Aquablation Compared to TURP: Efficacy and Ejaculatory Improvements Sustained (2019) (38)
A multicenter, randomized, double-blind, placebo controlled study of onabotulinumtoxinA 200 U to treat lower urinary tract symptoms in men with benign prostatic hyperplasia. (2014) (37)
Radical retropublc prostatectomy for localized carcinoma of the prostate in a large metropolitan hospital: Changing trends over a 10-year period (1984–1994) (1995) (37)
Prevention of benign prostatic hyperplasia disease. (2006) (37)
Reducing Infectious Complications Following Transrectal Ultrasound-guided Prostate Biopsy: A Systematic Review. (2016) (36)
Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies. (2014) (36)
Effects of tadalafil once daily on maximum urinary flow rate in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. (2014) (36)
Cost comparison for laparoscopic nephrectomy and open nephrectomy: analysis of individual parameters. (2002) (35)
Aquablation for benign prostatic hyperplasia in large prostates (80–150 mL): 6‐month results from the WATER II trial (2019) (35)
Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia (2007) (35)
Relationships among participant international prostate symptom score, benign prostatic hyperplasia impact index changes and global ratings of change in a trial of phytotherapy in men with lower urinary tract symptoms. (2013) (35)
Urethral luminal epithelia are castration‐insensitive cells of the proximal prostate (2020) (34)
Magnetic Resonance Imaging-guided In-bore and Magnetic Resonance Imaging-transrectal Ultrasound Fusion Targeted Prostate Biopsies: An Adjusted Comparison of Clinically Significant Prostate Cancer Detection Rate. (2019) (34)
The Cost of Prostate Cancer Chemoprevention: A Decision Analysis Model (2006) (34)
Implications of recent epidemiology studies for the clinical management of lower urinary tract symptoms (2009) (34)
Prognosis of patients with pelvic lymph node (LN) metastasis after radical prostatectomy: Value of extranodal extension and size of the largest LN metastasis (2014) (33)
Cluster analysis and lower urinary tract symptoms in men: findings from the Boston Area Community Health Survey (2008) (33)
Expression and characterization of full-length and partial human androgen receptor fusion proteins. Implications for the production and applications of soluble steroid receptors in Escherichia coli (1992) (33)
RESULTS OF THE PREDICT (PROSPECTIVE EUROPEAN DOXAZOSIN AND COMBINATION THERAPY) TRIAL (1999) (33)
Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6‐month, randomized, double‐blind study comparing finasteride plus tadalafil with finasteride pl (2015) (33)
Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts. (2007) (33)
Erratum: Transurethral needle ablation for benign prostatic hyperplasia: 12-month results of a prospective, Multicenter U.S. study (Urology (March 1998) 51 (415-421)) (1998) (33)
A prospective randomised placebo‐controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) (2018) (33)
The epidemiology of acute urinary retention in benign prostatic hyperplasia. (2001) (33)
Management of benign prostatic hyperplasia. (1997) (32)
Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial. (2016) (32)
The VIOXX in prostate cancer prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups* (2007) (32)
Safety and efficacy of Alfuzosin 10 mg once daily: a pooled analysis of three double-blind placebo-controlled studies (2002) (32)
Effect of tadalafil on male lower urinary tract symptoms: an integrated analysis of storage and voiding international prostate symptom subscores from four randomised controlled trials. (2015) (32)
Aspirin improves outcome in high risk prostate cancer patients treated with radiation therapy (2014) (32)
Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial. (2011) (31)
Differences in the rate of lymph node invasion in men with clinically localized prostate cancer might be related to the continent of origin (2007) (31)
Magnetic resonance/transrectal ultrasound fusion biopsy of the prostate compared to systematic 12-core biopsy for the diagnosis and characterization of prostate cancer: multi-institutional retrospective analysis of 389 patients. (2016) (31)
Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology. (1996) (31)
Prostatic Urethral Lift: A Unique Minimally Invasive Surgical Treatment of Male Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. (2016) (31)
Functional characteristics of the Camey ileal bladder. (1987) (30)
Validation of tertiary Gleason pattern 5 in Gleason score 7 prostate cancer as an independent predictor of biochemical recurrence and development of a prognostic model. (2015) (30)
The Agency for Health Care Policy and Research. Clinical guidelines for the diagnosis and treatment of benign prostatic hyperplasia. (1995) (30)
Pre‐treatment biomarker levels improve the accuracy of post‐prostatectomy nomogram for prediction of biochemical recurrence (2009) (30)
The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. (1996) (30)
Gleason score predicts androgen independent progression after androgen deprivation therapy. (2002) (30)
Early postoperative plasma transforming growth factor-beta1 is a strong predictor of biochemical progression after radical prostatectomy. (2008) (29)
PRE-TREATMENT BIOMARKER LEVELS IMPROVE THE ACCURACY OF POST-PROSTATECTOMY NOMOGRAM FOR PREDICTION OF BIOCHEMICAL RECURRENCE (2009) (29)
Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml. (2006) (29)
Assessment of Prospectively Assigned Likert Scores for Targeted Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsies in Patients with Suspected Prostate Cancer. (2016) (29)
Correlation of the International Prostate Symptom Score bother question with the Benign Prostatic Hyperplasia Impact Index in a clinical practice setting (2008) (29)
Single- versus dual-console robot-assisted radical prostatectomy: impact on intraoperative and postoperative outcomes in a teaching institution (2015) (28)
Actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia: temporal trends of prescription and hospitalization rates over 5 years in a large population of Italian men (2014) (28)
Prognostic value of syndecan‐1 expression in patients treated with radical prostatectomy (2007) (28)
Symptom relief and anejaculation after aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial (2018) (28)
Dutasteride reduces prostatitis symptoms compared with placebo in men enrolled in the REDUCE study. (2011) (28)
Safety and efficacy of the Alexandrite laser for the treatment of renal and ureteral calculi. (1998) (28)
Preoperative Plasma HER2 and Epidermal Growth Factor Receptor for Staging and Prognostication in Patients with Clinically Localized Prostate Cancer (2007) (27)
Blood biomarkers for prostate cancer detection and prognosis. (2007) (27)
Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies. (2006) (26)
Quantifying the contribution of symptom improvement to satisfaction of men with moderate to severe benign prostatic hyperplasia: 4-year data from the CombAT trial. (2012) (26)
Diagnostic Utility of a Likert Scale Versus Qualitative Descriptors and Length of Capsular Contact for Determining Extraprostatic Tumor Extension at Multiparametric Prostate MRI. (2018) (26)
Determining the Learning Curve for Robot-Assisted Simple Prostatectomy in Surgeons Familiar with Robotic Surgery. (2018) (26)
Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo-controlled study with terazosin. HYCAT Investigator Group. Hytrin Community Assessment Trial. (1997) (25)
Improved Magnetic Resonance Imaging-Pathology Correlation With Imaging-Derived, 3D-Printed, Patient-Specific Whole-Mount Molds of the Prostate (2017) (25)
Use of a prostate model to assist in training for digital rectal examination. (2000) (25)
Aquablation therapy for symptomatic benign prostatic hyperplasia: a single‐centre experience in 47 patients (2018) (25)
First-year costs of treating prostate cancer: estimates from SEER-Medicare data (2009) (25)
Estrogen receptor beta agonist LY500307 fails to improve symptoms in men with enlarged prostate secondary to benign prostatic hypertrophy (2014) (25)
Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium. (2007) (24)
Low Serum Testosterone Level Predisposes to Artificial Urinary Sphincter Cuff Erosion. (2016) (24)
Holmium Laser Enucleation of the Prostate for Men with Urinary Retention (2006) (24)
Lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction, and phosphodiesterase-5 inhibitors. (2004) (24)
False-positive serum prostate-specific antigen values in a patient with non-Hodgkin lymphoma of the kidney. (1995) (24)
Prostate Botulinum A Toxin Injection—An Alternative Treatment for Benign Prostatic Obstruction in Poor Surgical Candidates (2006) (24)
Economic analysis of finasteride: a model-based approach using data from the Proscar Long-Term Efficacy and Safety Study. (1999) (24)
Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia (2007) (24)
Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue trial (WATER) vs WATER II: comparing Aquablation therapy for benign prostatic hyperplasia in 30–80 and 80–150 mL prostates (2019) (23)
Incorporating Oxygen-Enhanced MRI into Multi-Parametric Assessment of Human Prostate Cancer (2017) (23)
Impact of dutasteride on nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): a pooled analysis of three phase III studies (2014) (23)
Bilateral synchronous testis tumors of different histology in a patient with the acquired immunodeficiency syndrome related complex. (1990) (23)
Redesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of Phytotherapy for Benign Prostatic Hyperplasia (2009) (22)
Re: Update on AUA Guideline on the Management of Benign Prostatic Hyperplasia (2011) (22)
Testing and referral patterns in the years surrounding the US Preventive Services Task Force recommendation against prostate‐specific antigen screening (2016) (22)
The role of transabdominal ultrasound in the preoperative evaluation of patients with benign prostatic hypertrophy. (1986) (22)
Durability of the Prostatic Urethral Lift: 2‐Year Results of the L.I.F.T. Study (2015) (22)
Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate cancer nomograms. (2007) (22)
THE EFFICACY AND SAFETY OF TADALAFIL ADMINISTERED ONCE A DAY FOR LOWER URINARY TRACT SYMPTOMS (LUTS) IN MEN WITH BENIGN PROSTATIC HYPERPLASIA (BPH) (2006) (22)
Meta-analysis of randomized clinical trials of finasteride. (1998) (22)
Association of overactive bladder and C‐reactive protein levels. Results from the Boston Area Community Health (BACH) Survey (2012) (21)
Development of nomogram to predict acute urinary retention or surgical intervention, with or without dutasteride therapy, in men with benign prostatic hyperplasia. (2006) (21)
Long-term pooled analysis of multicenter studies of cooled thermotherapy for benign prostatic hyperplasia results at three months through four years. (2004) (21)
Role of urinary cathepsin B and L in the detection of bladder urothelial cell carcinoma. (2008) (21)
Dutasteride significantly improves quality of life measures in patients with enlarged prostate (2008) (21)
Focus on lower urinary tract symptoms: nomenclature, diagnosis, and treatment options: highlights from the 5th international consultation on benign prostatic hyperplasia june 25-27, 2000, paris, france. (2001) (21)
Prevention of prostate cancer with finasteride. (2003) (20)
Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes. (2005) (20)
Quantitative diffusion‐weighted imaging and dynamic contrast‐enhanced characterization of the index lesion with multiparametric MRI in prostate cancer patients (2017) (20)
Prostate cancer detection using combined auto-fluorescence and light reflectance spectroscopy: ex vivo study of human prostates. (2014) (20)
Nocturia improvement in the combination of Avodart® and tamsulosin (CombAT) study (2014) (20)
The role of novel minimally invasive treatments for lower urinary tract symptoms associated with benign prostatic hyperplasia (2020) (20)
Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH (2009) (20)
EXPRESSION OF SURVIVIN AND APOPTOTIC BIOMARKERS IN BENIGN PROSTATIC HYPERPLASIA (2006) (20)
The Clinical Benefits of Dutasteride Treatment for LUTS and BPH. (2004) (20)
Low Testosterone Levels Result in Decreased Periurethral Vascularity via an Androgen Receptor-mediated Process: Pilot Study in Urethral Stricture Tissue. (2017) (20)
Acute relief or future prevention: is urology ready for preventive health care? (2000) (20)
Single‐cell analysis of mouse and human prostate reveals novel fibroblasts with specialized distribution and microenvironment interactions (2021) (19)
Laser Surgery Simulation Platform: Toward Full-Procedure Training and Rehearsal for Benign Prostatic Hyperplasia (BPH) Therapy (2011) (19)
Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the combination of avodart and tamsulosin trial (2011) (19)
Predictors of costs for robotic-assisted laparoscopic radical prostatectomy. (2011) (19)
The influence of body mass index on the cost of radical prostatectomy for prostate cancer (2010) (19)
Association of Cigarette Smoking, Alcohol Consumption and Physical Activity With Lower Urinary Tract Symptoms in Older American Men: Findings From the Third National Health and Nutrition Examination Survey (2006) (19)
– Benign Prostatic Hyperplasia A Systematic Review and Meta-analysis on the Use of Phosphodiesterase 5 Inhibitors Alone or in Combination with a-Blockers for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (2012) (18)
How I do it: Balloon tamponade of prostatic fossa following Aquablation. (2017) (18)
An initial negative round of targeted biopsies in men with highly suspicious multiparametric magnetic resonance findings does not exclude clinically significant prostate cancer-Preliminary experience. (2017) (18)
Prospective Inclusion of Apparent Diffusion Coefficients in Multiparametric Prostate MRI Structured Reports: Discrimination of Clinically Insignificant and Significant Cancers. (2019) (18)
Aquablation for benign prostatic hyperplasia in large prostates (80-150 cc): 2-year results. (2020) (18)
Idiopathic scrotal elephantiasis. (2005) (17)
Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL. (2007) (17)
The development of lonidamine for benign prostatic hyperplasia and other indications. (2005) (17)
Radical retropubic prostatectomy for localized carcinoma of the prostate in a large metropolitan hospital: changing trends over a 10-year period (1984-1994). Dallas Outcomes Research Group for Urological Disorders. (1995) (17)
Surgeon fatigue: impact of case order on perioperative parameters and patient outcomes. (2012) (17)
10 The impact of acute or chronic inflammation in baseline biopsy on the risk of progression in the MTOPS study (2005) (17)
Alpha2 macroglobulin, a PSA binding protein, is expressed in human prostate stroma (2005) (16)
A double-blind placebo-controlled study evaluating the onset of action of doxazosin gastrointestinal therapeutic system in the treatment of benign prostatic hyperplasia. (2005) (16)
The newly established guidelines for the diagnosis and management of benign prostatic hyperplasia (1995) (16)
Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride (2007) (16)
Long term follow-up study of the marsupialization technique for urethral diverticula in women. (1989) (16)
Dutasteride, a novel dual 5-A reductase inhibitor, reduces serum DHT to a greater extent versus finasteride and achieves finasteride maximal reduction in a larger proportion of patients (2003) (16)
Results of a 5-year multicenter trial of a new generation cooled high energy transurethral microwave thermal therapy catheter for benign prostatic hyperplasia. (2011) (16)
The Natural History of Lower Urinary Tract Dysfunction in Men: Minimum 10-Year Urodynamic Followup of Transurethral Resection of Prostate for Bladder Outlet Obstruction (2006) (15)
Clinical management of lower urinary tract symptoms with combined medical therapy (2008) (15)
Mucinous adenocarcinoma in defunctionalized bladders. (1995) (15)
Molecular pathogenesis of human prostate basal cell hyperplasia (2017) (15)
Drug treatment for LUTS and BPH: new is not always better. (2006) (15)
Are urologists fairly reimbursed for complex procedures: failure of 22 modifier? (2008) (15)
Updated results of a randomized, double-blind, multicenter sham-controlled trial of microwave thermotherapy with the Dornier Urowave in patients with symptomatic benign prostatic hyperplasia (1998) (15)
Beyond the cluster: methodological and clinical implications in the Boston Area Community Health survey and EPIC studies (2008) (15)
Prognostic value of insulin‐like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy (2012) (15)
Soluble gp130 regulates prostate cancer invasion and progression in an interleukin-6 dependent and independent manner. (2011) (15)
PROSPECTIVE DETERMINATION OF THE HORMONAL AND BIOCHEMICAL RESPONSE FOLLOWING LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) AGONIST WITHDRAWAL IN PATIENTS WITH ADVANCED PROSTATE CANCER (1999) (15)
Urodynamic standardization in a large‐scale, multicenter clinical trial examining the effects of daily tadalafil in men with lower urinary tract symptoms with or without benign prostatic obstruction (2010) (15)
1638: Baseline Post Void Residual Urine Volume as a Predictor of Urinary Outcomes in Men with BPH in the MTOPS Study (2005) (15)
Light Reflectance Spectroscopy to Detect Positive Surgical Margins on Prostate Cancer Specimens. (2016) (15)
The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge. (2005) (14)
Comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia: Long‐term results from the combination of dutasteride and tamsulosin study (2012) (14)
Effect of the dual 5 alpha-reductase inhibitor dutasteride on endocrine parameters and prostate volume (2002) (14)
Comparison of Tamsulosin and Naftopidil for Efficacy and Safety in the Treatment of Benign Prostatic Hyperplasia: A Randomized Controlled Trial (2006) (14)
Reporting of acute urinary retention in BPH treatment trials: importance of patient follow-up after discontinuation and case definitions. (2002) (14)
Temperature mapping in the canine prostate during transurethrally‐applied local microwave hyperthermia (1992) (14)
Verification and incorporation biases in studies assessing screening tests: prostate-specific antigen as an example. (2004) (14)
Sleep Problems are Associated with Development and Progression of Lower Urinary Tract Symptoms: Results from REDUCE (2018) (14)
Office-based therapies for benign prostatic hyperplasia: a review and update. (2019) (14)
Is screening for prostate cancer necessary in men with symptoms of benign prostatic hyperplasia? (1996) (13)
Is Benign Prostatic Hyperplasia a Risk Factor for Chronic Renal Failure (2006) (13)
Registry of Hypogonadism in Men (RHYME): design of a multi-national longitudinal, observational registry of exogenous testosterone use in hypogonadal men (2013) (13)
Laparoscopic Nephrectomy Is Cost Effective Compared With Open Nephrectomy in a Large County Hospital (2003) (13)
Natural history of ‘second’ biochemical failure after salvage radiation therapy for prostate cancer: a multi‐institution study (2018) (13)
Multi-Institutional Phase 2 Trial of High-Dose Stereotactic Body Radiation Therapy with Temporary Hydrogel Spacer for Low- and Intermediate-Risk Prostate Cancer (2017) (13)
RETROGRADE EJACULATION INDUCED BY SILODOSIN IS THE RESULT OF RELAXATION OF SMOOTH MUSCULATURE IN THE MALE URO-GENITAL TRACTS AND IS ASSOCIATED WITH GREATER URODYNAMIC AND SYMPTOMATIC IMPROVEMENTS IN MEN LUTS SECONDARY TO BPH (2009) (13)
Perioperative outcomes and cost of robotic vs open simple prostatectomy in the modern robotic era: results from the National Inpatient Sample (2020) (12)
Multiparametric Magnetic Resonance Imaging of the Prostate: Technical Aspects and Role in Clinical Management (2014) (12)
An Assessment of Patient Comfort and Morbidity After Robot-Assisted Radical Prostatectomy with Suprapubic Tube Versus Urethral Catheter Drainage. (2016) (12)
Methods of developing UWIN, the modified American Urological Association symptom score. (2011) (12)
α1-Blockers in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction: Is Silodosin Different? (2016) (12)
PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study (2018) (12)
The American Urological Association symptom index--concerns and confirmation. (1996) (12)
Urinary flow rate recording: the impact of a single dose of a diuretic on clinic logistics and flow rate parameters. (1999) (12)
Long-term results of a prospective, randomized clinical trial comparing tuna® to turp for the tretament of symptomatic bph (1997) (12)
Transurethral radiofrequency therapy for benign prostatic hyperplasia using a novel saline-liquid conductor: the virtual electrode. (2000) (11)
Are all α-blockers created equal? An update (2002) (11)
Reasons to go for Rezūm steam therapy: an effective and durable outpatient minimally invasive procedure (2020) (11)
Bolus Injection ν Drip Infusion Contrast Administration for Ureteral Stone Targeting During Shockwave Lithotripsy (1997) (11)
Placebo Response in Patients with Oral Therapy for Overactive Bladder: A Systematic Review and Meta-analysis. (2021) (11)
Validation of the modified American Urological Association symptom score. (2011) (11)
Currently available treatment guidelines for men with lower urinary tract symptoms (2008) (11)
Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment (2016) (11)
Efficacy and tolerability of the dual 5α-reductase inhibitor, dutasteride, in the treatment of benign prostatic hyperplasia in African-American men (2006) (11)
Dioxin Exposure and Benign Prostatic Hyperplasia (2006) (11)
Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride (2016) (11)
Evaluation of the impact of dutasteride/tamsulosin combination therapy on libido in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH): A post hoc analysis of a prospective randomised placebo‐controlled study (2018) (11)
Individualized pelvic physical therapy for the treatment of post-prostatectomy stress urinary incontinence and pelvic pain (2019) (11)
Combination medical therapy for lower urinary tract symptoms and benign prostatic hyperplasia. (2005) (11)
Benign prostatic hyperplasia and lower urinary tract symptom guidelines. (2013) (11)
Contemporary laparoscopic and open radical retropubic prostatectomy: pathologic outcomes and Kattan postoperative nomograms are equivalent. (2007) (10)
5-α-Reductase Inhibitors Prevent the Progression of Benign Prostatic Hyperplasia (2003) (10)
Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice (2006) (10)
Self management for men with lower urinary tract symptoms: randomised controlled trial (2007) (10)
First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia. (2003) (10)
Can we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study (2016) (10)
Feasibility of an Alternative Option for the Management of Male Lower Urinary Tract Symptoms. (2016) (10)
A prospective study of urologist-performed sonographic evaluation of the urinary tract in patients with prostatism. (1991) (10)
Diagnostic Performance of Prospectively Assigned Likert Scale Scores to Determine Extraprostatic Extension and Seminal Vesicle Invasion With Multiparametric MRI of the Prostate. (2019) (10)
Reasons to overthrow TURP: bring on Aquablation (2020) (10)
Long-term Outcome of Prostate Cancer Patients Who Exhibit Biochemical Failure Despite Salvage Radiation Therapy After Radical Prostatectomy (2017) (10)
Objective and subjective response criteria to diagnose benign prostatic hyperplasia. (1993) (9)
Reducing the risk of benign prostatic hyperplasia progression. (2002) (9)
IMPACT OF PROSTATE SIZE ON RESPONSE TO MEDICAL THERAPY FOR BENIGN PROSTATIC HYPERPLASIA (BPH): RESULTS OF THE PREDICT TRIAL (1999) (9)
BASELINE DATA FROM THE COMBINATION OF AVODART™ AND TAMSULOSIN (COMBAT) TRIAL: RELATIONSHIPS BETWEEN BODY MASS INDEX (BMI) AND LUTS/BPH MEASURES (2006) (9)
Detecting positive surgical margins: utilisation of light‐reflectance spectroscopy on ex vivo prostate specimens (2016) (9)
Thermal therapy in the treatment of benign prostatic hyperplasia (1997) (9)
Impact of Formulation on the Pharmacokinetics of Dutasteride: Results from Two Phase I Studies (2016) (9)
911: Impact of Baseline PSA and TRUS Volume on Longitudinal Changes in IPSS and Maximum Flowrate in MTOPS (2004) (9)
Erratum: The efficacy and safety of Tadalafil administered once a day for Lower Urinary Tract Symptoms (Luts) in Men with Bengin Prostatic Hyperplasia (BPH) (Journal of Sex Medicine (2007) vol. 4 (S91)) (2007) (8)
Prevention of AUR and surgery: 5α reductase inhibitors (5ARIS) provide superior benefits to α blockers (2003) (8)
Finasteride in Benign Prostatic Hyperplasia [2] (multiple letters) (2004) (8)
12-WEEK RESULTS OF A PHASE II TRIAL OF 100 AND 300 UNITS BOTULINUM NEUROTOXIN TYPE A (BONT-A) FOR THE MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) (2009) (8)
Preservation of Sexual Function 5 Years After Water Vapor Thermal Therapy for Benign Prostatic Hyperplasia. (2021) (8)
The novel dual 5α-reductase inhibitor dutasteride is effective for the treatment and prevention of complications in men with a PV 30≤40 CC and 40 CC (2003) (8)
The camey procedure: Preliminary results in 11 patients (1985) (8)
Safety and efficacy of the potassium-titanyl-phosphate laser and photoselective vaporization of the prostate for benign prostatic hyperplasia. (2006) (8)
The impact of dutasteride, a novel 5-α reductase inhibitor, on the hallmarks of BPH. Progression and outcomes (2002) (8)
Special applications of flexible deflectable ureterorenoscopy. (1989) (8)
POD-06.02: The effects of dutasteride, tamsulosin, and combination therapy on lower urinary tract symptoms and Qmax in men with BPH and prostatic enlargement: Two-year results from the Combination of Avodart ® and Tamsulosin (CombAT) study (2007) (8)
Gleason Grade Group Concordance between Preoperative Targeted Biopsy and Radical Prostatectomy Histopathologic Analysis: A Comparison Between In-Bore MRI-guided and MRI-Transrectal US Fusion Prostate Biopsies. (2021) (8)
Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH (2019) (8)
5‐Alpha reductase inhibitors induce a prostate luminal to club cell transition in human benign prostatic hyperplasia (2021) (8)
The management of acute urinary retention in France: a cross-sectional survey in 2618 men with benign prostatic hyperplasia (2007) (7)
CONVECTIVE RADIOFREQUENCY THERMAL THERAPY: DURABLE TWO‐YEAR OUTCOMES OF A RANDOMIZED CONTROLLED AND PROSPECTIVE CROSSOVER STUDY TO RELIEVE LOWER URINARY TRACT SYMPTOMS DUE TO BENIGN PROSTATIC HYPERPLASIA: PD23‐10 (2017) (7)
Post-Void Residual Urine Volume Is Not a Good Predictor of the Need for Invasive Therapy Among Patients With Benign Prostatic Hyperplasia (2006) (7)
5-alpha-Reductase Inhibitors Prevent the Progression of Benign Prostatic Hyperplasia. (2003) (7)
1077 Four year results from the largest, prospective, randomized study of prostatic urethral lift (PUL) (2016) (7)
Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial (2007) (7)
Herbal/Hormonal Dietary Supplement Possibly Associated with Prostate Cancer Progression (2008) (7)
THE RELATIONSHIP BETWEEN TESTOSTERONE LEVELS AND MEASURES OF SEXUAL DYSFUNCTION: BASELINE DATA FROM DUTASTERIDE STUDIES INVOLVING A TOTAL OF 12,464 SUBJECTS (2006) (7)
Medical Management for BPH: The Role of Combination Therapy (2006) (7)
A Multi-Institutional Phase II Trial of High-Dose SAbR for Prostate Cancer Using Rectal Spacer. (2021) (7)
Histologic upgrading in patients eligible for active surveillance on saturation biopsy. (2015) (7)
Aquablation of the prostate: a review and update. (2019) (7)
Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia (2019) (6)
A Randomized Controlled Trial Lower Urinary Tract Symptoms and Overactive Bladder : Tolterodine and Tamsulosin for Treatment of Men With (2006) (6)
When to Biopsy the Seminal Vesicles: A Validated Multiparametric Magnetic Resonance Imaging and Target Driven Model to Detect Seminal Vesicle Invasion of Prostate Cancer (2019) (6)
Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects (2007) (6)
BPH: a progressive disease of the ageing male (2002) (6)
Incidence and risk reduction of long-term outcomes: a comparison of benign prostatic hyperplasia with several other disease areas. (2000) (6)
WATER versus WATER II 2-Year Update: Comparing Aquablation Therapy for Benign Prostatic Hyperplasia in 30–80-cm3 and 80–150-cm3 Prostates (2021) (6)
Model‐based meta‐analysis of individual International Prostate Symptom Score trajectories in patients with benign prostatic hyperplasia with moderate or severe symptoms (2020) (6)
Prostatic Urethral Lift Versus Medical Therapy: Examining the Impact on Sexual Function in Men with Benign Prostatic Hyperplasia. (2021) (6)
Editorial: Fine-Tuning the Indication for Prostatectomy (1996) (6)
Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial (2008) (6)
Effect of estimated prostate volume on silodosin-mediated improvements in the signs and symptoms of BPH: does prostate size matter? (2011) (6)
Baseline serum prostate specific antigen (PSA) levels predict degree of symptom improvement following therapy of benign prostatic hyperplasia (BPH) with finasteride (1997) (6)
Best of the AUA Annual Meeting: Highlights From the 2010 American Urological Association Meeting, May 29-June 3, 2010, San Francisco, CA. (2010) (6)
Efficacy and tolerability of the dual 5alpha-reductase inhibitor, dutasteride, in the treatment of benign prostatic hyperplasia in African-American men. (2006) (6)
Stereotactic Ablative Radiotherapy for High-Risk Prostate Cancer-a Prospective Multi-level MRI-based Dose Escalation Trial. (2021) (6)
Is there a place for combination medical therapy? (2001) (6)
847: Institutional Variability in Predictive Accuracy of Urinary Cytology for Prediction of Transitional Cell Carcinoma Recurrence (2005) (6)
Diclofenac for Treatment of Nocturia Caused by Nocturnal Polyuria: A Prospective, Randomised, Double-Blind, Placebo-Controlled Crossover Study (2007) (5)
A randomized, blinded study comparing microwave thermotherapy (dornier urowave(tm)) with a sham procedure in patients with clinical benign prostatic hyperplasia (bph) (1997) (5)
The motion: Prevention of prostate cancer with a 5α-reductase inhibitor is feasible (2006) (5)
Ultrasonography in Urology: A Practical Approach to Clinical Problems (2002) (5)
The Management of Prostatic Obstruction: How to Determine the Best Options? (2003) (5)
LBA14 WATER VAPOR THERMAL THERAPY WITH REZUM SYSTEM: 3-YEAR RESULTS OF PROSPECTIVE CROSSOVER TRIAL REPLICATE DURABLE OUTCOMES OF PHASE III RANDOMIZED CONTROLLED STUDY FOR TREATMENT OF LOWER URINARY TRACT SYMPTOMS / BENIGN PROSTATIC HYPERPLASIA (2018) (5)
The assessment of patient complaints. (1994) (5)
7: Differences in Medical Management of LUTS/BPH between PCPS and Urologists (2006) (5)
12 The transition zone hypothesis in benign prostatic hyperplasia (2005) (5)
344 Baseline measures as predictors of clinical progression of benign prostatic hyperplasia (2004) (5)
Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. (2013) (5)
Prostate size: does it matter? (2000) (5)
Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression (2020) (5)
The motion: Prevention of prostate cancer with a 5α-reductase inhibitor is feasible (2006) (5)
Statin use and longitudinal changes in prostate volume; results from the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial (2019) (5)
PII-LBA1 USING THE THERMAL ENERGY OF CONVECTIVELY DELIVERED WATER VAPOR FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS DUE TO BENIGN PROSTATIC HYPERPLASIA: THE REZUM II STUDY (2015) (5)
Natural History of Prostatism: Risk Factors for Acute Urinary Retention (1997) (5)
For the motion (2006) (5)
Five-year outcomes for Aquablation therapy compared to TURP: results from a double-blind, randomized trial in men with LUTS due to BPH. (2022) (5)
The UroLift implant: mechanism behind rapid and durable relief from prostatic obstruction (2021) (5)
176 EXAMINATION OF THE RELATIONSHIP BETWEEN PROSTATE INFLAMMATION, LOWER URINARY TRACT SYMPTOMS AND CLINICAL PROSTATITIS-LIKE SYMPTOMS: BASELINE DATA FROM THE REDUCE TRIAL (2007) (5)
Saw palmetto for benign prostatic hyperplasia: just how effective is it? (2006) (5)
Are Over‐the‐Counter Alpha Blockers in the Best Interest of Men with Lower Urinary Tract Symptoms? (2017) (5)
Prospective , Randomized , Double-Blind , Vehicle Controlled , Multicenter Phase IIb Clinical Trial of the Pore Forming Protein PRX 302 for Targeted Treatment of Symptomatic Benign Prostatic Hyperplasia (2013) (5)
Lower Urinary Tract Symptoms are Associated With Depressive Symptoms in White, Black and Hispanic Men in the United States (2008) (5)
Determination of stone-forming risk by measuring crystal formation in whole urine with gel model. (1986) (4)
1640: Development of a Nomogram to Predict Acute Urinary Retention or BPH-Related Surgery with or without Medical Therapy in Men with BPH Based on Data from the MTOPS Trial (2005) (4)
Are all alpha-blockers created equal? An update. (2002) (4)
Heterogeneity of 5 α-Reductase Gene Expression in Benign Prostatic Hyperplasia (2003) (4)
532: Distribution of Gleason Scores Among Men Discovered to Have Prostate Cancer (CAP) in the Medical Therapy of Prostatic Symptoms (MTOPS) Trial (2005) (4)
Heterogeneity of 5 alpha-reductase gene expression in benign prostatic hyperplasia. (2003) (4)
Key Clinical Trials in BPH (2003) (4)
Potentially harmful effect of a testosterone dietary supplement on prostate cancer growth and metastasis. (2008) (4)
Meta-analysis with individual data of functional outcomes following Aquablation for lower urinary tract symptoms due to BPH in various prostate anatomies (2021) (4)
THE RELATIONSHIP BETWEEN AGE, PROSTATE VOLUME, SERUM TESTOSTERONE AND SERUM PSA IN MEN WITH CLINICAL BPH (1999) (4)
Formalin disinfection of prostate biopsy needles may reduce post-biopsy infectious complications (2017) (4)
Clinical Efficacy of Silodosin in Patients with Severe Lower Urinary Tract Symptoms Related to Benign Prostatic Obstruction: A Pooled Analysis of Phase 3 and 4 Trials. (2020) (4)
Solitary recurrence of castration-resistant prostate cancer with low or undetectable levels of prostate specific antigen salvaged with local ablative radiation therapy: A case report. (2016) (4)
Some socio-economic issues surrounding prostatectomy: the US experience. (1994) (4)
Preemptive analgesia for prostatectomy. (1998) (4)
Seminal Plasma Cytokines and Chemokines in Prostate Inflammation: Interleukin 8 as a Predictive Biomarkers in Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Benign Prostatic Hyperplasia (2007) (4)
FACTORS ASSOCIATED WITH CHANGES IN BENIGN PROSTATIC HYPERPLASIA (BPH) MANAGEMENT IN CLINICAL PRACTICE: LONGITUDINAL RESULTS FROM THE BPH REGISTRY (2008) (4)
Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis. (2021) (4)
The role of the general practitioner in the diagnosis and treatment of benign prostatic hyperplasia (BPH). (1994) (4)
Effect of scrambling on the short-term reliability of the American Urological Association Symptom Index. (1999) (4)
MP-20.23: Tolterodine extended release (TER) and/or Tamsulosin (TAM) in men with lower urinary tract symptoms (LUTS) including overactive bladder (OAB): effects of serum prostate-specific antigen (PSA) level (2007) (4)
Benign prostatic hyperplasia: an update on minimally invasive therapy including Aquablation. (2020) (4)
Benign Prostatic Hyperplasia Treatment On Its Way to Precision Medicine: Dream or Reality? (2022) (4)
Progression of leukoplakia of the bladder to squamous cell carcinoma 19 years after complete urinary diversion. (1988) (4)
1487 TRAINING LASER PROSTATE SURGERY WITH AN ADVANCED SIMULATION BASED CURRICULUM: THE VICTOR® greenlight trainer (2011) (4)
LBA01-06 FIVE YEAR RESULTS OF THE PROSPECTIVE, RANDOMIZED CONTROLLED TRIAL OF WATER VAPOR THERMAL THERAPY FOR TREATMENT OF LOWER URINARY TRACT SYMPTOMS DUE TO BENIGN PROSTATIC HYPERPLASIA (2020) (3)
Combination Medical Therapy for Male Lower Urinary Tract Symptoms (2014) (3)
Conference on Evaluation and Managment of Benign prostatic Hyperplasia, Cambridge, Massachusets, March 31 2001: Introduction (2001) (3)
The assessment of medical treatment for benign prostatic hyperplasia (BPH). (1994) (3)
1096 Combination therapy with finasteride and tadalafil once daily for 6 months: A randomized, placebo-controlled study in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia (2013) (3)
Management of Male Lower Urinary Tract Symptoms in a Simulated, Over-the-Counter Setting: An Exploratory Study of Tamsulosin (2019) (3)
2116 PROSTATIC URETHRAL LIFT FURTHER CHARACTERIZED: A MULTI-CENTER EXPERIENCE (2011) (3)
Photoselective Potassium-Titanyl-Phosphate Laser Vaporization of the Benign Obstructive Prostate: Observations on Long-Term Outcomes (2006) (3)
6: Differences Between PCPS and Urologists in the Evaluation of Men with LUTS/BPH (2006) (3)
Endocrine therapies for BPH: scientific rationale, clinical results, and patient selection. (1994) (3)
Long term (5 year) results from the largest, prospective, randomized, controlled study of the minimally invasive prostatic urethral lift (PUL) (2017) (3)
Bolus injection v drip infusion contrast administration for ureteral stone targeting during shockwave lithotripsy. (1998) (3)
MP-20.28: Dutasteride provides greater improvement in symptoms and Qmax than tamsulosin in men with moderate-to-severe symptoms of BPH and prostate enlargement: Two-year results from the Combination of Avodart ® and Tamsulosin (CombAT) study (2007) (3)
Over-the-counter medication availability could augment self-management of male lower urinary tract symptoms (2018) (3)
1350: Relationships between Alcohol Use and Measures of LUTS/BPH Severity: Baseline Data from Dutasteride Studies Involving a Total of 18,914 Subjects (2006) (3)
INTERMEDIATE TERM OUTCOMES OF TUNA FOR BPH: 36 MO RESULTS OF THE TUNA VS TURP U.S. RANDOMIZED STUDY (1999) (3)
Model‐based meta‐analysis of the time to first acute urinary retention or benign prostatic hyperplasia‐related surgery in patients with moderate or severe symptoms (2020) (3)
4: Correlation of International Prostate Symptom Score Bother Question with the Benign Prostatic Hyperplasia Impact Index and SF-12 in a Practice Setting (2005) (3)
Notice of duplicate publication: "Potentially harmful effect of a testosterone dietary supplement on prostate cancer growth and metastasis" (arch intern med. 2008;168[2]:235-236). (2008) (3)
RELATIONSHIP BETWEEN SERUM PSA AND TOTAL PROSTATE AND TRANSITION ZONE VOLUME IN MEN WITH CLINICAL BPH (1999) (3)
PD5-01 THREE YEAR DURABILITY OF THE PROSTATIC URETHRAL LIFT FOR BPH: RESULTS OF A PROSPECTIVE, MULTI-CENTER, RANDOMIZED STUDY (2015) (3)
What's New in Aquablation. (2018) (3)
Rationale for the inclusion of alpha-adrenergic blockade in benign prostatic hyperplasia treatment guidelines (1996) (3)
CHANGES IN BLADDER OUTLET OBSTRUCTION INDEX IN MEN WITH SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA TREATED WITH TADALAFIL (2009) (3)
1565: Initial Results of a Randomized Multi-Center Trial Comparing the Efficacy and Safety of Indigo Optima Laser Treatment with Tamsulosin in Men with LUTS and BPH (2005) (3)
21: Development of a Highly Accurate Nomogram for Prediction of the Need for Exploration in Patients with Renal Trauma (2007) (3)
1426: Pre-Operative Plasma Endoglin Levels Predict Metastasis to Lymph Nodes and Disease Progression in Patients Treated with Radical Prostatectomy (2007) (3)
1439: Alpha Adrenergic Stimulation Regulates Cox-2 Expression in Prostate Stroma Cells (2005) (3)
914: Duration of Dihydrotestosterone Suppression Following Discontinuation of Dutasteride: Implications for Missed Doses (2004) (3)
1780 MIST2: BASELINE PSA AND TOTAL PROSTATE VOLUME PREDICTS CLINICAL RESPONSE TO INTRAPROSTATIC INJECTION OF BOTULINUM TOXIN FOR THE MANAGEMENT OF LUTS (2010) (3)
1366: Influence of Age on Outcome of Trial Without Catheter (TWOC) During Alfuzosin 10 MG OD Therapy in Patients With Acute Urinary Retention (AUR) Related to BPH (2004) (3)
The effect of combined androgen ablation on the expression of alpha1A‐adrenergic receptor in the human prostate (2004) (3)
IMPROVEMENTS IN STORAGE AND VOIDING SYMPTOMS WITH DUTASTERIDE, TAMSULOSIN AND THE COMBINATION: POST- HOC ANALYSIS OF THE 2-YEAR DATA FROM THE CombAT TRIAL (2008) (3)
Urethral luminal epithelia are castration-insensitive progenitors of the proximal prostate (2020) (3)
PNFLBA-03 THE WATER STUDY CLINICAL RESULTS – A PHASE III BLINDED RANDOMIZED PARALLEL GROUP TRIAL OF AQUABLATION VS. TRANSURETHRAL RESECTION OF THE PROSTATE WITH BLINDED OUTCOME ASSESSMENT FOR MODERATE-TO-SEVERE LUTS IN MEN WITH BENIGN PROSTATIC HYPERPLASIA (2017) (3)
910: Impact of Baseline Symptom Severity on Threshold Changes to Trigger Crossing Over to Active Therapy in MTOPS Trial (2004) (2)
Morbidity, Mortality and Early Outcome of Transurethral Resection of the Prostate: A Prospective Multicenter Evaluation of 10,654 Patients: Reich O, Gratzke C, Bachmann A, et al (Ludwig-Maximilians-Univ Munich, Germany) J Urol 180:246-249, 2008 § (2008) (2)
THE PROSTATIC URETHRAL LIFT: A NOVEL MINIMALLY INVASIVE TREATMENT FOR LOWER URINARY TRACT SYMPTOMS SECONDARY TO BENIGN PROSTATIC HYPERPLASIA (2009) (2)
283Improved correlations between serum PSA and prostate volume measures in the biopsy subset of patients in MTOPS (2005) (2)
MP71-08 TWO YEAR DURABILITY OF THE PROSTATIC URETHRAL LIFT: MULTI-CENTER PROSPECTIVE STUDY (2014) (2)
SERUM PROSTATE SPECIFIC ANTIGEN (PSA) AND THE RATIO OF PSA TO PROSTATE VOLUME (PSAD) IN AFRICAN AMERICAN AND CAUCASIAN MEN (1999) (2)
MEDICAL MANAGEMENT OF LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA (LUTS/ BPH): DIFFERENCES BETWEEN UROLOGISTS AND PRIMARY CARE PHYSICIANS (PCPS) (2006) (2)
1782 CLINICAL OUTCOMES BY BASELINE PROSTATE VOLUME IN MEN WITH BENIGN PROSTATIC HYPERPLASIA: 4 YEAR RESULTS FROM THE COMBINATION OF AVODART AND TAMSULOSIN (COMBAT) TRIAL (2010) (2)
Protective Association between Nonsteroidal Antiinflammatory Drug Use and Measures of Benign Prostatic Hyperplasia: St Sauver JL, Jacobson DJ, McGree ME, et al (Mayo Clinic, Rochester, Minn; Southern California Permanente Med Group, Pasadena) Am J Epidemiol 164:760–768, 2006 § (2007) (2)
Long-term consequences of castration in men (1999) (2)
DECISION‐MAKING IN MEN CONSIDERING USE OF NON‐PRESCRIPTION TAMSULOSIN FOR LOWER URINARY TRACT SYMPTOMS: MP09‐12 (2017) (2)
5α-Reductase Inhibition in the Treatment of LUTS and BPH: Update and Importance of Dual Inhibition of Types 1 and 2 (2004) (2)
WATER vs WATER II: Comparing Aquablation Therapy for Benign Prostatic Hyperplasia in 30cc-80cc and 80cc-150cc Prostates. (2019) (2)
PD09-02 PROSTATE CANCER SCREENING AND REFERRAL PATTERNS IN THE YEARS SURROUNDING THE UNITED STATES PREVENTATIVE SERVICES TASK FORCE RECOMMENDATION AGAINST PSA SCREENING IN ALL MEN (2016) (2)
Optimizing the management of prostate diseases: prostatitis and benign prostatic hyperplasia. Introduction. (2008) (2)
644 Systematic review and meta-analysis of the use of phosphodiesterase type 5 inhibitors (pde5-is) alone or in combination with alpha blockers for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) (2012) (2)
239 Testosterone treatment is not associated with increased risk of prostate cancer or cardiovascular events: Results from the Registry of Hypogonadism in Men (RHYME) (2015) (2)
PATIENT PERCEPTIONS OF THE EFFECT OF MEDICAL THERAPY FOR BENIGN PROSTATIC HYPERTROPHY (BPH) IN THE PREDICT TRIAL (1999) (2)
MP-20.24: Tolterodine extended release (TER) and/or Tamsulosin (TAM) in men with lower urinary tract symptoms (LUTS) including overactive bladder (OAB): effects of prostate size (2007) (2)
ALFUZOSIN 10MG ONCE DAILY PREVENTS BPH OVERALL CLINICAL PROGRESSION BUT NOT ACUTE URINARY RETENTION OCCURRENCE: RESULTS OF A 2-YEAR PLACEBO-CONTROLLED STUDY (2006) (2)
Progression and remission of urologic symptoms in the community: results of a longitudinal cluster analysis approach. (2014) (2)
Two-year outcomes after aquablation compared to TURP: Results from a blinded randomized trial (2020) (2)
CHANGES IN LOWER URINARY TRACT SYMPTOMS (LUTS) IN MEN RECEIVING MEDICAL THERAPY FOR BENIGN PROSTATIC HYPERPLASIA (BPH): LONGITUDINAL OUTCOMES FROM THE BPH REGISTRY (2008) (2)
Convective Radio Frequency Thermal Therapy for Treatment of Benign Prostatic Hyperplasia: Single Office Experience with 255 Patients over 4 Years (2019) (2)
Relationships between Participants' International Prostate Symptom Score and BPH Impact Index Changes and Global Ratings of Change in a Trial of Phytotherapy for Men with Lower Urinary Tract Symptoms (2014) (2)
Update on Prostate-Specific Antigen Testing for the Early Detection of Prostate Cancer (2008) (2)
Minimally invasive therapies for benign prostatic hyperplasia. Discussion (2001) (2)
THE EFFECTS OF TUNA AND TURP ON PRESSURE-FLOW URODYNAMIC PARAMETERS: ANALYSIS OF THE US RANDOMIZED STUDY (1999) (2)
1253 A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE USE OF PHOSPHODIESTERASE TYPE 5 INHIBITORS (PDE5-IS) FOR LOWER URINARY TRACT SYMPTOMS (LUTS) SECONDARY TO BENIGN PROSTATIC HYPERPLASIA (BPH) (2012) (2)
CORRELATION BETWEEN PSA AND PROSTATE SIZE MEASURED BY TRANSRECTAL ULTRASONOGRAPHY (TRUS) (1999) (2)
MP69-14 THE RISK OF PROSTATE CANCER ON SUBSEQUENT BIOPSIES IN MEN WITH HIGH-GRADE PIN AND/OR ASAP IN A PROSPECTIVE STUDY WITH CENTRAL PATHOLOGY (THE REDUCE TRIAL) (2014) (2)
The placebo and nocebo effects in functional urology (2021) (2)
Safety and outcome of stereotactic body radiation therapy (SBRT) with rectal hydrogel spacer for prostate cancer. (2020) (2)
642 Tadalafil 5 mg once daily improves lower urinary tract symptoms suggestive of benign prostatic hyperplasia in men without erectile dysfunction (2012) (2)
Physical Activity, Benign Prostatic Hyperplasia, and Lower Urinary Tract Symptoms (2008) (2)
Does Peak Urine Flow Rate Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from REDUCE (2017) (2)
IMPROVEMENTS IN PATIENT-REPORTED QUALITY OF LIFE WITH DUTASTERIDE, TAMSULOSIN AND THE COMBINATION: 2-YEAR RESULTS FROM THE COMBINATION OF AVODART AND TAMSULOSIN (COMBAT) TRIAL (2008) (2)
341 Long-term dutasteride therapy results in sustained reductions in total prostate volume in men with symptomatic benign prostatic hyperplasia (2004) (2)
973 COST COMPARISON OF ROBOTIC, LAPAROSCOPIC AND OPEN RADICAL PROSTATECTOMY (2009) (2)
PD6-12 SINGLE VERSUS DUAL CONSOLE ROBOT ASSISTED LAPAROSCOPIC PROSTATECTOMY: IMPACT ON INTRAOPERATIVE AND POSTOPERATIVE OUTCOMES (2014) (2)
PD21-02 PROSPECTIVE, RANDOMIZED, BLINDED STUDY OF PROSTATIC URETHRAL LIFT (PUL): FOUR YEAR RESULTS (2016) (2)
Modeling prostate cancer detection probability using prostate specific antigen , transition and peripheral zone volumes , and numbers of biopsy cores (2)
838Measurement of the effect of dutasteride on worry and embarrassment associated with lower urinary tract symptoms in men BPH: Use of novel instrument (2005) (2)
The placebo effect in the treatment of benign prostatic hyperplasia (2005) (2)
Expert panel debate (1) (2006) (2)
1553: Intermediate Results of a Multi-Center Trial of a New Generation Cooled TUMT for BPH (2005) (2)
UIJ - Lower urinary tract symptoms (LUTS), symptom overlap, psychosocial impact, and cardiovascular disease in men: Findings from the boston area community health survey (BACH) (2008) (1)
498 HIGH RATES FOR CONTINUED BPH MEDICAL THERAPY AMONG NON RESPONDERS (2010) (1)
THE HEALTH IMPROVEMENT NETWORK (THIN) DATABASE: FOCUSED SAFETY STUDY OF ACUTE URINARY RETENTION (AUR) IN MEN (2009) (1)
Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL. (2009) (1)
PD-02.06 (2006) (1)
European patients with benign prostatic hyperplasia (BPH): Differences in sexual dysfunction (1997) (1)
Improved imaging-pathology correlation with MR imaging-derived, 3D-printed, patient-specific whole-mount molds of the prostate. (2017) (1)
990 CLINICAL OUTCOMES AFTER COMBINATION THERAPY WITH DUTASTERIDE AND TAMSULOSIN IN MEN WITH BENIGN PROSTATIC HYPERPLASIA (BPH) BY BASELINE CHARACTERISTICS: 4 YEAR RESULTS FROM THE RANDOMIZED, DOUBLE-BLIND, COMBAT TRIAL (2010) (1)
1635: Prostate Specific Antigen (PSA) and Post Void Residual (PVR) Urine Volume Predict Relapse of Urinary Retention and Need for Surgery in Patients with Benign Prostatic Hyperplasia (BPH) After a First Episode of Acute Urinary Retention (AUR) (2005) (1)
Meta-analysis of holmium laser enucleation versus transurethral resection of the prostate for symptomatic prostatic obstruction: Tan A, Liao C, Mo Z, et al (Guangxi Medical University, China) Br J Surg 94:1201-1208, 2007 § (2008) (1)
Reliability of digital rectal examination (ore) measures to assess prostate size relative to transrectal ultrasonography (trus) (1997) (1)
258: Baseline Body Mass Index (BMI) and the Development of Prostate Cancer (CAP) in the Medical Therapy of Prostatic Symptoms (Mtops) Trial (2005) (1)
Sexual function and benign prostatic hyperplasia. (1999) (1)
Dutasteride Improves Nocturia but Does Not Lead to Better Sleep: Results from the REDUCE Clinical Trial. (2021) (1)
1433: Association of Blood Levels of Components of the Urokinase System of Plasminogen Activation with Prostate Cancer Presence, Invasion, Progression, and Metastasis (2007) (1)
Understanding Treatment Response in Individual Profiles of Men with Prostatic Enlargement at Risk of Progression. (2022) (1)
1783 EFFICACY OF DUTASTERIDE ON BENIGN PROSTATIC HYPERPLASIA ENDPOINTS IN THE REDUCTION BY DUTASTERIDE OF PROSTATE CANCER EVENTS (REDUCE) STUDY ACCORDING TO BASELINE INTERNATIONAL PROSTATE SYMPTOM SCORE AND PROSTATE VOLUME (2010) (1)
Dutasteride is associated with reduced risk of transrectal prostate biopsy-associated urinary tract infection and related hospitalizations (2017) (1)
PD22-09 MANAGEMENT OF MALE LOWER URINARY TRACT SYMPTOMS IN A SIMULATED OVER-THE-COUNTER SETTING: AN EXPLORATORY, ACTUAL-USE STUDY OF AN ALPHA BLOCKER (2016) (1)
IMPACT OF BASELINE VARIABLES ON THE RISK OF LUTS PROGRESSION, AUR AND BPH-RELATED SURGERY: RESULTS OF A 2-YEAR PLACEBO-CONTROLLED STUDY WITH ALFUZOSIN 10MG ONCE DAILY (2006) (1)
Peri-operative Outcomes of Robotic-assisted simple prostatectomy versus Thulium Fiber Laser Enucleation of the Prostate (2018) (1)
1439: Combining Transition Zone Biopsy Composition with Transition Zone Volume to Predict Progression in the Mtops Trial (2006) (1)
Advances in the treatment of lower urinary tract symptoms and benign prostatic hyperplasia: highlights from the 21st European association of urology congress, april 5-8, 2006, paris, france. (2006) (1)
915: Does Hypogonadism (Testosterone <300 NG/DL) Affect Prostate Function or Response to Dutasteride?: Analysis of Data from Dutasteride Phase III BPH Studies (2004) (1)
Validation of BPH-related questionnaires in sixteen counties: Advancing age and decreased understanding (1998) (1)
921: Association between Ejaculatory Dysfunction and Therapy Among Men Enrolled in the BPH Registry & Patient Survey (2006) (1)
LB-S&T-04 PROSPECTIVE, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED, MULTINATIONAL, PHASE 3 CLINICAL TRIAL OF THE PORE FORMING PROTEIN PRX302 FOR TARGETED TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (2016) (1)
Five-Year Follow-up of Feedback Microwave Thermotherapy Versus TURP for Clinical BPH: A Prospective Randomized Multicenter Study: Mattiasson A, Wagrell L, Schelin S, et al (Lund Univ, Sweden; Uppsala Univ, Sweden; Kalmar County Hosp, Sweden; et al) Urology 69:91–97, 2007 § (2007) (1)
340 Long-term dutasteride therapy results in continued improvements in symptoms and peak urinary flow in men with symptomatic benign prostatic hyperplasia (2004) (1)
PD23-07 INCREASED DETECTION OF HIGHER GRADE PROSTATE CANCER WITH MRI-FUSION PROSTATE BIOPSY AT HIGHER PSA (2018) (1)
444: Effect of Dutasteride on the Incidence of Prostate Cancer (PCA) in Men with Benign Prostatic Hyperplasia (2004) (1)
Ultrasound of the Prostate: Imaging in the Diagnosis and Therapy of Prostatic Disease, 2nd ed (1997) (1)
RACE SPECIFIC DIFFERENCES IN SERUM PSA, PROSTATE VOLUME, AND OUTCOME OF TRUS GUIDED BIOPSIES (1999) (1)
Filling vs. Voiding Symptoms as Predictors of Benign Prostatic Hyperplasia-Related Outcomes (1999) (1)
A urodynamic comparison of patients with Parkinsons disease and males with lower urinary tract symptoms Distinguishing neurogenic from non-neurogenic detrusor overactivity (2003) (1)
Historical Overview of Medical Therapy for Benign Prostatic Hyperplasia (2005) (1)
Rapid reduction in risk of AUR and/or surgery with finasteride in men with benign prostatic hyerplasia (2002) (1)
1641: Impact of Baseline Variables on the Risk of LUTS and BPH Progression in Placebo and Alfuzosin Treated Patients: Results of the 2 Years Altess Study (2006) (1)
Placebo-Controlled Dose-Ranging Phase 2 Study of Subcutaneously Administered LHRH Antagonist Cetrorelix in Patients with Symptomatic Benign Prostatic Hyperplasia: Debruyne F, Gres AA, Arustamov DL (Academic Hospital Nijmegen, 6500 The Netherlands; Urology MOKB, 223 052 Minsk, Belarus; Ministry of He (2008) (1)
Best of the 2007 AUA Annual Meeting: Highlights from the 2007 Annual Meeting of the American Urological Association, May 19-24, 2007, Anaheim, CA. (2007) (1)
Advances in the Medical Treatment of Prostate Cancer, Bladder Cancer, Renal Cell Cancer, and Benign Prostatic Hyperplasia: Highlights from the XVIIth Congress of the European Association of Urology, Birmingham, UK, February 23-26, 2002. (2003) (1)
PSA density is associated with BPH cellular composition (2022) (1)
DUTASTERIDE AND TAMSULOSIN COMBINATION THERAPY PROVIDES GREATER IMPROVEMENTS IN PATIENT-REPORTED QUALITY OF LIFE COMPARED WITH EITHER DRUG ALONE: 2-YEAR RESULTS FROM THE COMBINATION OF AVODART® AND TAMSULOSIN (CombAT) TRIAL (2008) (1)
59 CLUSTER PATTERNS IN MALE AND FEMALE UROLOGIC SYMPTOMS: HOW MUCH CHANGE OCCURS IN THE PATTERN OF SYMPTOMS OVER TIME? (2011) (1)
1559: Alfuzosin 10MG Once Daily is Well Tolerated in Elderly and Antihypertensive Patients in the Long-Term (2007) (1)
Botulinum Toxin Type A Improves Benign Prostatic Hyperplasia Symptoms in Patients With Small Prostates: Chuang Y-C, Chiang P-H, Huang C-C, et al (Chang Gung Mem Hosp, Kaohsiung, Taiwan; Univ of Pittsburgh, Pa) Urology 66:775–779, 2005 § (2006) (1)
1348: Explanatory Variables for Measures of Sexual Dysfunction in LUTS/BPH and Prostate Cancer Risk Reduction Studies: Baseline Data from Dutasteride Studies Involving a Total of 18,914 Subjects (2006) (1)
Microscopic hematuria screening in a male consumer population with lower urinary tract symptoms (2015) (1)
REPRODUCIBILITY OF REPEAT URODYNAMIC ASSESSMENTS FROM A MULTICENTER TRIAL IN MEN WITH SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA FOLLOWING 12 WEEKS OF PLACEBO TREATMENT (2009) (1)
Sexual and prostate health in a longitudinal, European cohort study: The Registry of Hypogonadism in Men (RHYME). (2010) (1)
Response and Rebuttal to Editorial Commentary on "Erectile and Ejaculatory Function Preserved With Convective Water Vapor Energy Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Randomized Controlled Study". (2016) (1)
1362: Change in Symptom Severity Status in 4-Year Dutasteride Studies in Men With Symptomatic BPH (2004) (1)
Magnetic Resonance Imaging Features Associated with Histology of Benign Prostatic Hyperplasia Nodules: Generation of a Predictive Model. (2021) (1)
1704: Ability of the Transition Zone Index to Predict Changes in Symptoms and Maximum Flow Rate in Men with BPH Treated with Placebo Versus Dutasteride (2005) (1)
MP16-04 A COMPARISON OF PROSTATE CANCER DETECTION AT 3T MRI WITH AND WITHOUT AN ENDORECTAL COIL: A PROSPECTIVE, PAIRED-PATIENT STUDY (2016) (1)
Predictors of response to the prostatic urethral lift (PUL) treatment (2018) (1)
Restoration of Continence after Prostatectomy Is Associated with Weight Loss: A Pilot Study. (2021) (1)
336 TADALAFIL 5 MG ONCE DAILY IMPROVES ERECTILE DYSFUNCTION (ED) AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH-LUTS) IN MEN WITH BOTH ED AND BPH-LUTS: RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTINATIONAL STUDY (2011) (1)
347 A double-blind, placebo-controlled study to evaluate the onset of action of doxazosin gastrointestinal therapeutic system (GITS) in the treatment of BPH (soarx-early onset) (2004) (1)
913: Long-Term Dutasteride Therapy Results in Continued Improvements in Symptoms and Peak Urinary Flow in Men with Symptomatic Benign Prostatic Hyperplasia (2004) (1)
1257 IS THE TADALAFIL EFFECT ON LOWER URINARY TRACT SYMPTOMS RELATED TO SEVERITY OF ERECTILE DYSFUNCTION AND IS ITS EFFECT ON ERECTILE DYSFUNCTION RELATED TO SEVERITY OF LOWER URINARY TRACT SYMPTOMS (2012) (1)
Metabolic consequences of urinary diversion with intestinal segments. (1998) (1)
CONTINUING RESULTS OF A MULTI-CENTER TRIAL OF A NEW GENERATION COOLED TRANS URETHRAL MICROWAVE THERAPY FOR BENIGN PROSTATIC HYPERPLASIA (2008) (1)
RELATIONSHIPS BETWEEN BASELINE SERUM PSA AND PSA CHANGES, AND PROSTATE VOLUME AND VOLUME CHANGES OVER FOUR YEARS IN PATIENTS ON PLACEBO AND FINASTERIDE (1999) (1)
RELATIONSHIP BETWEEN SERUM PSA AND TRUS MEASURED TOTAL AND TRANSITION ZONE VOLUME OF THE PROSTATE IN MEN WITH BPH IN THE MTOPS TRIAL (1999) (1)
Seniority of primary care physicians is associated with a decrease in PSA ordering habits in the years surrounding the United States Preventative Services Task Force recommendation against PSA screening. (2018) (1)
Baseline bother and symptom scores determine which BPH subjects will be bothered following treatment (2003) (1)
MP-09.09 (2006) (1)
Therapeutic treatment for benign prostatic hyperplasia (2005) (1)
471 URODYNAMIC EFFECTS OF TADALAFIL 20 MG ONCE DAILY VERSUS PLACEBO IN MEN WITH SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (2009) (1)
1639: Development of a Nomogram to Predict Symptom Progression with or without Medical Therapy in Men with BPH Based on Data from the MTOPS Trial (2005) (1)
THE UTILITY OF ULTRASOUND DERIVED PROSTATE PARAMETERS IN PREDICTING CLINICAL RESPONSE IN MEN TREATED WITH BOTULINUM NEUROTOXIN TYPE A (BONT-A) FOR BENIGN PROSTATIC HYPERPLASIA (BPH) (2009) (1)
PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study (2016) (1)
5 YEAR PROSPECTIVE, RANDOMIZED, CONTROLLED STUDY RESULTS ON THE MINIMALLY INVASIVE PROSTATIC URETHRAL LIFT (PUL): PD27‐01 (2017) (1)
Serum Prostate-Specific Antigen to Predict the Presence of Bladder Outlet Obstruction in Men with Urinary Symptoms (2006) (1)
Improving the Safety of TURP. (2000) (1)
151 BPH registry: New men's sexual scale correlates sexual dysfunction to severity of IPSS (2004) (1)
PD21-04 TREATMENT OF LOWER URINARY TRACT SYMPTOMS DUE TO BENIGN PROSTATIC HYPERPLASIA WITH CONVECTIVE WATER VAPOR ENERGY ABLATION: PRESERVED ERECTILE AND EJACULATORY FUNCTION (2016) (1)
Re: complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. (2004) (1)
Combination therapy in the treatment of BPH (2005) (1)
Correlation between risk factors for vascular disease and the American Urological Association Symptom Score (2007) (1)
DO UROLOGIC SYMPTOMS CLUSTER AMONG WOMEN? RESULTS FROM THE BOSTON AREA COMMUNITY HEALTH SURVEY (2008) (1)
002 Simulated Over-the-counter use of Tamsulosin by Men with Urinary Symptoms (2018) (1)
IS PSA INFLUENCED BY TESTOSTERONE LEVELS IN AGING MEN (2008) (1)
Evaluating Surgical Outcomes of Robot Assisted Simple Prostatectomy in the Retreatment Setting. (2022) (1)
Statin use and longitudinal changes in prostate volume; results from the REDUCE trial. (2019) (1)
1286: The Relationship between PSA Isoforms and BPH-Related Prostate Volume at Baseline in the MTOPS Trial (2005) (1)
Pedicled preputial patch in repair of minor penile chordee with or without hypospadias. (1993) (1)
1710: Measurement of the Effect of Dutasteride on Disease-Related Lifestyle Adaptations in Men with Symptomatic BPH: Use of a Novel Instrument (2005) (1)
THE PERFORMANCE OF PSA, PSAD, AND TRANSITION ZONE PSAD IN 210 PATIENTS EVALUATED BY A SINGLE EXAMINER (1999) (1)
1974 COMPARISON OF BENIGN PROSTATIC HYPERPLASIA OUTCOMES IN THE COMBINATION OF AVODART AND TAMSULOSIN (COMBAT) AND REDUCTION OF DUTASTERIDE IN CANCER EVENTS (REDUCE) STUDIES (2011) (1)
EFFECT OF PHOSPHODIESTERASE TYPE 5 INHIBITOR USE ON LOWER URINARY TRACT SYMPTOMS IN MEN WITH BENIGN PROSTATIC HYPERPLASIA (BPH): RESULTS FROM THE BPH REGISTRY (2008) (1)
An Actual Use Study of Tamsulosin in Men with Bothersome Urinary Symptoms in a Simulated Over-the-Counter Setting (2020) (1)
1557: Relationship between Screening IPSS and the Placebo Run-In Response in the Pooled Reduce and Combat Population (2007) (1)
MP62-05 OUTCOMES ASSESSMENT OF AQUABLATION IN PROSTATES 50 TO 80ML IN VOLUME - A SUBGROUP ANALYSIS FROM THE PHASE III BLINDED RANDOMIZED WATER STUDY COMPARING AQUABLATION VS. TRANSURETHRAL RESECTION OF THE PROSTATE FOR MODERATE-TO-SEVERE LUTS IN MEN WITH BPH (2018) (1)
1493: Cancer Detection Rate and Grade Shift in PCPT are Reflections of Finasteride-Induced Changes in Prostate Volume and Tumor Shrinkage: Results of a Mathematical Modeling Study (2006) (0)
1980 EFFECT OF DUTASTERIDE ON THE DETECTION OF PROSTATE CANCER IN MEN WITH BENIGN PROSTATIC HYPERPLASIA IN THE COMBINATION OF AVODART AND TAMSULOSIN (COMBAT) STUDY (2010) (0)
LBA01-02 IMPACT OF MEDICAL TREATMENT ON STORAGE VS VOIDING SYMPTOMS AND NOCTURIA FREQUENCY: A DYNAMIC NOMOGRAM N=9167 MEN WITH PROSTATIC ENLARGEMENT (2023) (0)
PD11-09 CELLULAR MECHANISMS OF 5-ALPHA REDUCTASE INHIBITOR TREATMENT RESISTANCE IN BENIGN PROSTATIC HYPERPLASIA (2021) (0)
New Strategies for Bladder and Prostate Cancer, BPH Explored by South Central Urologists: Highlights from the South Central Section of the American Urological Association January 16-20, 1999, Cancun, Mexico. (1999) (0)
Issue Information (2020) (0)
238: Combined Effect of Apoptotic Biomarkers on Bladder Cancer Recurrence and Mortality after Radical Cystectomy (2007) (0)
PD15-02 PRACTICE TIME OF PRIMARY CARE PHYSICIANS IS ASSOCIATED WITH CHANGE IN PSA ORDERING HABITS IN THE YEARS SURROUNDING THE UNITED STATES PREVENTATIVE SERVICES TASK FORCE RECOMMENDATION AGAINST PSA SCREENING (2016) (0)
MP-09.08 (2006) (0)
Rapid Communication Aquablation for Benign Prostatic Hyperplasia in Large Prostates (80-150 cc): 1-Year Results (2019) (0)
Reply by Authors: "Prospective Monitoring and Adapting Strategies for Prevention of Infection Following Transrectal Prostate Procedures". (2018) (0)
1288: Improved Correlations between Serum PSA and Prostate Volume Measures in the Biopsy Subset of Patients in MTOPS (2005) (0)
DEMOGRAPHIC AND CLINICAL PARAMETERS ASSOCIATED WITH USE OF MEDICAL THERAPY AT ENROLMENT IN THE BPH REGISTRY AND PATIENT SURVEY (2006) (0)
469: The Prostate Cancer Prevention Trial: Implications on Survival Outcomes (2004) (0)
PD39-12 THE CO-OCCURRING SYNDROME - OVERLAP OF ED AND BPH AND THEIR CLINICAL CORRELATES IN AGING MEN: RESULTS FROM THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY. (2015) (0)
PD23-04 MEN WITH ERECTILE DYSFUNCTION AND LOWER URINARY TRACT SYMPTOMS SECONDARY TO BENIGN PROSTATIC HYPERPLASIA WITH PROSTATIC ENLARGEMENT WHO RESPONDED TO TADALAFIL/FINASTERIDE CO-ADMINISTRATION THERAPY: RESULTS FROM A RANDOMIZED, PLACEBO-CONTROLLED STUDY (2014) (0)
NEOADJUVANT AND ADJUVANT alpha-BLOCKADE TO IMPROVE EARLY RESULTS OF HIGH-ENERGY TRANSURETHRAL MICROWAVE THERMOTHERAPY (TUMT): RESULTS OF A PROSPECTIVE, RANDOMIZED CLINICAL TRIAL (1999) (0)
Do Prostatic Infarction, Prostatic Inflammation and Prostate Morphology Play a Role in Acute Urinary Retention? (2006) (0)
537: Saturation Biopsy Does Not Influence Serum PSA Values or PSA Velocity (2005) (0)
MP-09.16 (2006) (0)
Introduction (2008) (0)
DIAGNOSTIC PERFORMANCE AND REPRODUCIBILITY OF A LIKERT SCALE VERSUS QUALITATIVE DESCRIPTORS FOR DETERMINATION OF EXTRAPROSTATIC TUMOR EXTENSION WITH MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING OF THE PROSTATE: PD61‐06 (2017) (0)
Holmium Laser Enucleation of Prostate for Patients in Urinary Retention (2006) (0)
747 Incidence of benign prostatic hyperplasia clinical progression over time in the combination of avodart and tamsulosin (CombAT) study (2012) (0)
HIGH-ENERGY TRANSURETHRAL MICROWAVE THERMOTHERAPY (TUMT) VERSUS alpha-BLOCKER TREATMENT FOR BEING PROSTATIC HYPERPLASIA(BPH): A PROSPECTIVE, RANDOMIZED CLINICAL TRIAL (1999) (0)
Best of the AUA Annual Meeting: Highlights From the 2011 American Urological Association Meeting, May 14-19, 2011, Washington, DC. (2011) (0)
PD56-05 THREE-YEAR OUTCOMES AFTER AQUABLATION COMPARED TO TURP: EFFICACY AND EJACULATORY IMPROVEMENTS SUSTAINED (2020) (0)
Fine-tuning the indication for prostatectomy. (1996) (0)
MP01-02 WHAT MINIMAL IMPORTANT DIFFERENCE IN URINARY SYMPTOM RELIEF BENEFITS PATIENT QUALITY OF LIFE? – ASSOCIATED WITH REZūM WATER VAPOR THERMAL THERAPY 4 YEAR OUTCOMES (2019) (0)
Autonomic Nervous System Overactivity in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: McVary KT, Rademaker A, Lloyd GL, et al (Northwestern Univ, Chicago) J Urol 174:1327–1333, 2005 § (2006) (0)
748 Effect of baseline variables on acute urinary retention and surgery related to benign prostatic hyperplasia in men from the combination of avodart and tamsulosin (CombAT) study (2012) (0)
Internationale- und USA-Leitlinien (2000) (0)
Benign Prostatic Hyperplasia: Epidemiology, Evaluation & Medical Non-Surgical Therapy PSA DENSITY IS CORRELATED WITH BPH CELLULAR COMPOSITION POST-VOIDED RESIDUAL URINE RATIO IS A PREDICTOR OF BLADDER OUTLET OBSTRUCTION IN MEN WITH LOWER URINARY TRACT SYMPTOMS: DEVELOPMENT OF A CLINICAL NOMOGRAM (2022) (0)
IMPROVED PREDICTION OF DISEASE RELAPSE AFTER RADICAL PROSTATECTOMY USING A PANEL OF PREOPERATIVE BLOOD-BASED BIOMARKERS (2008) (0)
Saw palmetto for benign prostatic hyperplasia. (2007) (0)
Utility of blood oxygen level dependent magnetic resonance imaging in the evaluation of tissue oxygenation patterns of prostate cancer. (2013) (0)
1633: Alfuzosin 10mg Once Daily Prevents BPH Overall Clinical Progression but not the Aur Occurrence: A 2-Year Placebo-Controlled Study (2006) (0)
1709: Beliefs and Actual Prescribing Habits for Medical Therapy for LUTS/EP Among American Men and Physicians: Results of A Survey (2005) (0)
PD39-01 PSA DENSITY IS CORRELATED WITH BPH CELLULAR COMPOSITION (2022) (0)
1918 UPDATE ON THE PROSTATIC URETHRAL LIFT, A NOVEL MINIMALLY INVASIVE TREATMENT FOR SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (2010) (0)
910 CAVEOLIN-1 OVEREXPRESSION IS ASSOCIATED WITH AGGRESSIVE PROSTATE CANCER RECURRENCE (2007) (0)
Convective radiofrequency water vapor thermal therapy for benign prostatic hyperplasia: a single office experience (2017) (0)
Localized Prostate Cancer Factor / Scatter Factor Levels in Patients with Clinically Predictive Value of Plasma Hepatocyte Growth (2008) (0)
TOTAL COST IN THE 1ST YEAR FOLLOWING DIAGNOSIS OF PROSTATE CANCER: ESTIMATES FROM US SEER-MEDICARE DATA (2008) (0)
Issue Information (2020) (0)
The effects of anticoagulant use in high-risk prostate cancer treated with radiotherapy on overall survival and biochemical control. (2014) (0)
Open to debate. The motion: prevention of prostate cancer with a 5alpha-reductase inhibitor is feasible. (2006) (0)
PD33-02 IMPACT OF EARLY VS. DELAYED INITIATION OF DUTASTERIDE/TAMSULOSIN COMBINATION THERAPY IN LOWER URINARY TRACT SYMPTOMS/BENIGN PROSTATIC HYPERPLASIA (LUTS/BPH) PATIENTS WITH MODERATE TO SEVERE SYMPTOMS AT RISK FOR PROGRESSION (2020) (0)
Discussion following Dr. Roehrborn's presentation (2001) (0)
912 CIRCULATING LEVELS OF PLASMINOGEN ACTIVATION INHIBITOR-1 IMPROVE THE ACCURACY OF PRE-AND POST-OPERATIVE NOMOGRAMS FOR PREDICTION OF PROSTATE CANCER RECURRENCE AFTER RADICAL PROSTATECTOMY (2007) (0)
Practice Patterns in Benign Prostatic Hyperplasia Surgical Therapy: The Dramatic Increase in Minimally Invasive Technologies: Yu X, Elliott SP, Wilt TJ, et al (University of Minnesota, Minneapolis) J Urol 180:241-245, 2008 § (2008) (0)
PD06-07 AGGRESSIVENESS OF PROSTATE CANCER: CORRELATION BETWEEN PROSPECTIVELY ASSIGNED APPARENT DIFFUSION COEFFICIENT VALUES AND ISUP GRADE GROUP (2018) (0)
Phase I Dose-Escalation Trial of Stereotactic Ablative Body Radiotherapy (SAbR) for Men with High-Risk Prostate Cancer (2020) (0)
Longitudinal Association between Prostatitis and Development of Benign Prostatic Hyperplasia: St Sauver JL, Jacobson DJ, McGree ME, et al (Mayo Clinic, Rochester, MN) Urology 71:475-479, 2008 § (2008) (0)
1509: Factors Responsible for Failure to Recruit in a Clinical Trial Comparing Minimally Invasive Surgical Therapy with Combination Drug Treatment for Benign Prostatic Hyperplasia (2006) (0)
1646: Clinically Meaningful (Perceptible) Changes in Symptom Scores During Long-Term Dutasteride Therapy in Men with Benign Prostatic Hyperplasia (2005) (0)
Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men: Parsons JK, Bergstrom J, Barrett-Connor E (Univ of California San Diego School of Med, San Diego, La Jolla, CA) BJU Int 101:313-318, 2007 § (2008) (0)
CAN PATIENTS WITH LUTS AND BPH DISCERN CHANGES IN PEAK URINARY FLOW RATE AND DO SUCH CHANGES CONTRIBUTE TO OVERALL SATISFACTION WITH TREATMENT (2009) (0)
PD23-02 COMPARING PREDICTORS OF DURABILITY AFTER PROSTATIC URETHRAL LIFT (PUL) BETWEEN REAL WORLD AND CONTROLLED STUDIES (2021) (0)
Medical Management of Benign Prostatic Obstruction (2001) (0)
Reply by Authors. (2021) (0)
Female Urethral Diverticula – Diagnosis, Treatment and Long Term Follow-Up (1987) (0)
Association of Interleukin-4 and Interleukin-1 Receptor Antagonist Gene Polymorphisms and Risk of Benign Prostatic Hyperplasia: Konwar R, Gara R, Singh M, et al (Central Drug Res Inst, Lucknow; King George Med Univ, Lucknow) Urology 71:868-872, 2008 § (2008) (0)
1389: Variation in IRB Review of a Multi-Center Clincial Trial Study Protocol (2005) (0)
A Double-blind Placebo-controlled Study Evaluating the Onset of Action of Doxazosin Gastrointestinal Therapeutic System in the Treatment of Benign Prostatic Hyperplasia (2006) (0)
MP30-09 PROSPECTIVELY ASSIGNED POSITIVE CONTRAST ENHANCEMENT SCORE DETECTS MORE CLINICALLY SIGNIFICANT PROSTATE CANCER IN MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING USING PI-RADS V2 (2019) (0)
Metabolic Implications of Continent Urinary Diversions (1987) (0)
Combined Use of α-Adrenergic and Muscarinic Antagonists for the Treatment of Voiding Dysfunction: Ruggieri MR Sr, Braverman AS, Pontari MA (Temple Univ, Philadelphia) J Urol 174:1743–1748, 2005 § (2006) (0)
THE LONG-TERM SAFETY AND EFFICACY OF TERAZOSIN ADMINISTERED ONCE DAILY IN MEN WITH SYMPTOMATIC BPH: RESULTS OF A 48 MONTHS EXTENSION STUDY (1999) (0)
New aspects in medical therapy for BPH (1997) (0)
MP40-12 ESTABLISHING A MINIMAL CLINICALLY MEANINGFUL DIFFERENCE IN THE MSHQ: NEW INSIGHTS (2019) (0)
THE INFLUENCE OF BASELINE PARAMETERS ON CHANGES IN IPSS WITH DUTASTERIDE, TAMSULOSIN, AND COMBINATION THERAPY: TWO-YEAR DATA FROM THE COMBINATION OF AVODART® AND TAMSULOSIN (COMBAT) STUDY (2008) (0)
BPH and Enlarged Prostate Progression: What the Primary Care Physician Needs to Know (2006) (0)
IMPACT OF SAMPLING DENSITY ON INITIAL 10 OR MORE (+) CORE PROSTATE BIOPSY: DEVELOPMENT AND INTERNAL VALIDATION OF A 10+ CORES BIOPSY NOMOGRAM (2006) (0)
MP32-20 PROSTATIC URETHRAL LIFT VS. MEDICAL THERAPY: A META-ANALYSIS EXAMINING SEXUAL FUNCTION OUTCOMES IN MEN WITH BPH (2020) (0)
PD43-02 THE IMPACT OF CASE ORDER ON POSITIVE SURGICAL MARGINS FOR PROSTATE CANCER: A MULTI-INSTITUTIONAL ANALYSIS (2020) (0)
PD16-09 HYPOGONADISM IS A RISK FACTOR FOR ARTIFICIAL URINARY SPHINCTER CUFF EROSION (2016) (0)
Prospective Evaluation of the Learning Curve for Holmium Laser Enucleation of the Prostate (2007) (0)
889: Predictive Accuracy, Sensitivity, and Specificity of Nuclear Matrix Protein 22 and Urine Cytology for Prediction of Recurrence of Non-Transitional Cell Carcinoma of the Bladder (2006) (0)
Meta-analysis comparison of sexual function outcomes after treatment with prostatic urethral lift or medical therapy (2020) (0)
LIGHT‐REFLECTANCE SPECTROSCOPY TO DETECT POSITIVE SURGICAL MARGINS AT RADICAL PROSTATECTOMY: EXPLORATION OF NEW ALGORITHMS TO REFINE DETECTION RATE: PD10‐08 (2017) (0)
MP-05.18 A Prospective Multi-Center Study of the Efficacy and Safety of the AMS Green Light Laser HPS in Men with Male LUTS and Clinical BPH (2011) (0)
MP45-11 THE WATER STUDY CLINICAL RESULTS – RESULTS AT 1 YEAR AND URODYNAMIC FINDINGS. (2019) (0)
Treatment of Men With Lower Urinary Tract Symptoms and Overactive Bladder—Reply (2007) (0)
1335: Alpha 1A Stimulation on Map Kinases Activation in Prostate Stromal Cells (2004) (0)
POD-10.11: Long-term Efficacy of Combination Therapy with the Dual 5-α Reductase Inhibitor Dutasteride and the α-Blocker Tamsulosin in the Treatment of Benign Prostatic Hyperplasia: 4-year Results from the Randomized, Double-blind, CombAT Trial (2009) (0)
Acknowledgement to Reviewers (2008) (0)
PD40-12 IMPACT OF SINGLE DOSE PERIOPERATIVE ENOXAPARIN ON RATE OF THROMBOEMBOLIC EVENTS FOLLOWING ROBOTIC ASSISTED PROSTATECTOMY: A HOSPITAL SYSTEM-WIDE ANALYSIS (2019) (0)
Management of benign prostatic hypertrophy (2004) (0)
Sensitivity of multiparametric MRI and targeted biopsy for detection of adverse pathologies (Cribriform gleason pattern 4 and intraductal carcinoma): Correlation of detected and missed prostate cancer foci with whole mount histopathology. (2022) (0)
329 SYMPTOM, FLOW RATE AND QUALITY OF LIFE IMPROVEMENTS BY PROSTATE VOLUME IN THE COMBINATION OF AVODART AND TAMSULOSIN (COMBAT) STUDY OF MEN WITH BENIGN PROSTATIC HYPERPLASIA (2011) (0)
Effects of a Shared Protocol Between Urologists and General Practitioners on Referral Patterns and Initial Diagnostic Management of Men With Lower Urinary Tract Symptoms in Italy: The Prostate Destination Study (2006) (0)
Best of the 2008 AUA Annual Meeting: Highlights from the 2008 Annual Meeting of the American Urological Association, May 17-22, 2008, Orlando, FL. (2008) (0)
470 ONCE DAILY TADALAFIL IMPROVED SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA IN MEN WITH OR WITHOUT HISTORY OF ERECTILE DYSFUNCTION (2009) (0)
UroLift and Rezum: minimally invasive surgical therapies for the management of benign prostatic hyperplasia. (2021) (0)
MP57-20 DELINEATION OF PROSTATE CANCER FROM BPH BY EXCESS PSA RELATIVE TO PREDICTED: A STUDY IN MEN UNDERGOING MRI-TARGETED BIOPSY (2018) (0)
eview – Female Urology – Incontinence ower Urinary Tract Symptoms Revisited : A Broader linical Perspective hristopher (2008) (0)
MP22-12 MAGNETIC RESONANCE IMAGING FEATURES ASSOCIATED WITH HISTOLOGY OF BENIGN PROSTATIC HYPERPLASIA NODULES: A PREDICTIVE MODEL (2021) (0)
Holmium laser enucleation of the prostate for prostates of > 125 mL: Matlaga BR, Kim SC, Kuo RL, et al (Methodist Hosp/Clarian Health Partners, Indianapolis, Ind; Indiana Univ, Indianapolis) BJU Int 97:81–84, 2006 § (2007) (0)
MP04-11 CORRELATION OF MRI PROSTATE VOLUME WITH SERUM PROSTATE-SPECIFIC ANTIGEN IN MEN WITH NEGATIVE STANDARD AND MRI-FUSION BIOPSIES (2018) (0)
Transurethral Lower Tract Procedures (2022) (0)
1324: Survivin Expression is Associated With Characteristics of Benign Prostatic Hyperplasia (2004) (0)
Dutasteride in the treatment of the BPH patient (2005) (0)
Long term efficacy of the express targis cooled thermotherapy compared with the original treatment for benign prostatic hyperplasia (2001) (0)
1285: The Correlation between Luts (AUA-SS) and Erectile Dysfunction (SHIM) in an Age Matched Racially Diverse Male Population: Data from the Prostate Cancer Awareness Week (PCAW) (2005) (0)
39-year-old man with voiding symptoms. (2004) (0)
Erratum: Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: A randomized, placebo-controlled trial (Prostate Cancer and Prostatic Diseases (2007) vol. 10 (155-159) 10.1038/sj.pcan.4500925)) (2008) (0)
MP48-03 PREOPERATIVE URINE CULTURES FOR PROSTHETIC UROLOGICAL SURGERY: WHAT IS THE EVIDENCE? (2016) (0)
Sexually Transmitted Infections, Prostatitis, Ejaculation Frequency, and the Odds of Lower Urinary Tract Symptoms (2006) (0)
Urology: Editorial comment (2001) (0)
MP35-01 IMPACT OF PROSTATE INFLAMMATION ON 4 YEAR INCIDENCE, SEVERITY, AUR AND SYMPTOM PROGRESSION OF BENIGN PROSTATIC HYPERPLASIA (2016) (0)
EARLY POST-OPERATIVE PLASMA TGF-β1 IS A STRONG PREDICTOR OF BIOCHEMICAL PROGRESSION AFTER RADICAL PROSTATECTOMY (2008) (0)
MP06-01 IDENTIFICATION OF COGNATE PROXIMAL CELL TYPES OF THE MOUSE AND HUMAN PROSTATE AND THEIR ENRICHMENT IN HUMAN BENIGN PROSTATIC HYPERPLASIA (2020) (0)
Discussion following Dr. Steers' presentation (2001) (0)
192 Five Year Sexual Function Results of the Multi-Center, Prospective, Randomized Study of the Prostatic Urethral Lift (PUL) (2018) (0)
Standard Treatment Modality for Ureteral Calculi (2003) (0)
Correction: The UroLift implant: mechanism behind rapid and durable relief from prostatic obstruction (2022) (0)
MP-09.19: Why men on watchful waiting for LUTS/BPH start medical therapy: findings from the USA BPH Registry & Patient Survey (2006) (0)
PD05-12 SCHEDULED KETOROLAC REDUCES POST-OPERATIVE NARCOTIC NEEDS WITHOUT INCREASED RISK OF COMPLICATIONS IN PATIENTS UNDERGOING ROBOTIC ASSISTED SIMPLE PROSTATECTOMY (2020) (0)
PD56-11 SINGLE PORT ROBOTIC ASSISTED SIMPLE PROSTATECTOMY IS ASSOCIATED WITH DECREASED POST-OPERATIVE NARCOTIC USE (2020) (0)
PREDICTIVE VALUE OF HEPATOCYTE GROWTH FACTOR/SCATTER FACTOR (HGF/SF) IN PATIENTS WITH CLINICALLY LOCALIZED PROSTATE CANCER (2008) (0)
MP25-10 AQUABLATION FOR BENIGN PROSTATIC HYPERPLASIA IN LARGE PROSTATES (80-150CC) (2020) (0)
Does proximity of positive prostate biopsy core to capsular margin help predict side-specific extracapsular extension at prostatectomy? (2019) (0)
Shared Care and the Management of Lower Urinary Tract Symptoms: Wolters R, Wensing M, Klomp M, et al (Univ Med Centre St Radboud, Nijmegen, The Netherlands) BJU Int 94:1287–1290, 2004 § (2006) (0)
Lower Urinary Tract Symptoms in Men: Self-perceptions and the Concept of Bother: Gannon K, Glover L, O'Neill M, et al (Univ of East London; Univ of Hull, England; Littlemore Hosp, Oxford, England; et al) BJU Int 96:823–827, 2005 § (2006) (0)
Aquablation of the prostate: a review and update. (2021) (0)
PD41-06 POOLED ANALYSIS OF 330+ SUBJECTS TREATED WITH THE PROSTATIC URETHRAL LIFT (PUL) REVEALS UNDERTREATMENT IMPACTS DURABILITY (2023) (0)
MP06-14 CHARACTERIZING THE CELLULAR PATHOGENESIS OF BPH THROUGH SINGLE CELL RNA SEQUENCING OF NORMAL AND HYPERPLASTIC HUMAN PROSTATE (2019) (0)
Meta-analysis of randomized, placebo-controlled clinical trials of terazosin (1997) (0)
MP-09.07 (2006) (0)
High Presalvage Radiation Therapy Prostate-Specific Antigen Strongly Correlates With Very Early Failure, Which Leads to Worse Outcome (2015) (0)
MP74-01 MULTIPARAMETRIC PROSTATE MRI STRUCTURED REPORT INFORMS PREOPERATIVELY OF RISK FOR POSITIVE APICAL SURGICAL MARGINS DURING RADICAL PROSTATECTOMY (2020) (0)
333 ALPHA BLOCKER INITIATION IN THE REDUCE STUDY (2011) (0)
Spotlight on Bladder and Prostate Cancer and Urinary Retention at Glasgow Gathering: Highlights from the BAUS Annual Meeting June 21-25, 1999, Glasgow, Scotland. (2000) (0)
Cluster analysis and lower urinary tract symptoms in men: findings from the Boston Area Community Health Survey: Çinar A, Hall SA, Link CL, et al (New England Research Inst, Watertown, MA; et al) BJU Int 101:1247-1256, 2008 § (2008) (0)
The Effects of Tamsulosin and Sildenafil in Separate and Combined Regimens on Detailed Hemodynamics in Patients With Benign Prostatic Enlargement (2007) (0)
Ultrasonography of the kidney and bladder (1989) (0)
Optical properties of ex-vivo prostate tissues and the design of trans-rectal ultrasound coupled optical probe (2014) (0)
PRE-OPERATIVE PLASMA HER2 AND EGFR FOR STAGING AND PROGNOSTICATION IN PATIENTS WITH CLINICALLY LOCALISED PROSTATE CANCER (2008) (0)
Identifying predictors of antispasmodic use following robotic assisted simple prostatectomy. (2022) (0)
Review Article 1 -ADRENERGIC RECEPTORS AND THEIR INHIBITORS IN LOWER URINARY TRACT SYMPTOMS AND BENIGN PROSTATIC HYPERPLASIA (2004) (0)
1248 PHOSPHODIESTERASE TYPE 5 INHIBITOR USE IN THE COMBINATION OF AVODART® AND TAMSULOSIN (COMBAT) STUDY (2012) (0)
Bladder ultrasonography. (1994) (0)
344 PREDICTORS OF SEXUAL DYSFUNCTION IN OLDER MEN: BASELINE DATA FROM THE REDUCE TRIAL (2007) (0)
MP17-11 COST EFFECTIVENESS OF MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING FOR DETECTION OF PROSTATE CANCER (2015) (0)
MP-09.17: Differences between PCPs and urologists in the medical treatment of men with LUTS/BPH (2006) (0)
MP46-19 MULTI-INSTITUTIONAL COMPARISON AND EXPERIENCE OF UPGRADING RATES OF STANDARD VS. TARGETED PROSTATE BIOPSIES (2018) (0)
ECONOMIC IMPLICATIONS OF EFFECTS OF FINASTERIDE ON THE RISK OF ACUTE URINARY RETENTION AND NEED FOR SURGERY (1999) (0)
2335 SOLUBLE GP130 PROMOTES PROSTATE CANCER INVASION AND PROGRESSION IN AN IL-6 INDEPENDENT FASHION (2011) (0)
ADVANCES IN THE PHARMACOLOGIC TREATMENT OF BPH Efficacy of-Adrenergic Receptor Blockers in the Treatment of Male Lower Urinary Tract Symptoms (2010) (0)
REPLY (2012) (0)
Correction: The UroLift implant: mechanism behind rapid and durable relief from prostatic obstruction (2022) (0)
The changing landscape of upper tract urothelial carcinoma management. (2020) (0)
PD28-03 PREOPERATIVE TELEHEALTH EVALUATION ALONE PRIOR TO UROLOGIC SURGERY: SAFETY, FEASIBILITY, SURGICAL OUTCOMES (2021) (0)
IMPACT OF PRIMARY CARE PHYSICIAN FACTORS ON ADHERENCE TO UNITED STATES PREVENTATIVE SERVICES TASK FORCE RECOMMENDATION AGAINST PSA SCREENING: PD40‐11 (2017) (0)
MP18-15 REAL WORLD MALE VOIDING BEHAVIOR AND VARIABILITY USING AN AUDIO-BASED UROFLOWMETRY APPLICATION (2022) (0)
PD-02.08 (2006) (0)
LBA1 Efficacy and safety of DuodartTM treatment versus watchful waiting (WW) with step-up therapy to tamsulosin in the management of men with treatment-naïve, prostate enlargement, increased prostate-specific antigen (PSA) and moderately symptomatic benign prostatic hyperplasia (BPH): 2-Year CONDUCT (2014) (0)
PD64-01 THE WATER STUDY CLINICAL RESULTS – A PHASE III BLINDED RANDOMIZED TRIAL OF AQUABLATION VS. TURP WITH BLINDED OUTCOME ASSESSMENT FOR MODERATE-TO-SEVERE LUTS IN MEN WITH BPH (2018) (0)
915 THE INFLUENCE OF BODY MASS INDEX ON THE COST OF RADICAL PROSTATECTOMY FOR PROSTATE CANCER (2010) (0)
MP42-17 PATIENTS MEETING ACTIVE SURVEILLANCE CRITERIA ON SATURATION BIOPSY ARE AT HIGH RISK FOR HISTOLOGIC GRADE PROGRESSION ON PROSTATECTOMY (2014) (0)
PD10-11 CONVECTIVE RADIOFREQUENCY THERMAL THERAPY FOR TREATMENT OF BPH: 4 YEAR FOLLOW UP FROM A SINGLE OFFICE EXPERIENCE (2019) (0)
1427: Circulating Levels of Plasminogen Activation Inhibitor-1 Improve the Accuracy of Pre- and Post-Operative Nomograms for Prediction of Prostate Cancer Recurrence after Radical Prostatectomy (2007) (0)
MP62-07 PREDICTORS OF RESPONSE TO THE PROSTATIC URETHRAL LIFT TREATMENT (2018) (0)
MP01-11 POOLED ANALYSIS OF BLADDER FUNCTION POST-AQUABLATION (2021) (0)
MP42-19 A MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING (MPMRI) PILOT STUDY OF PROSTATIC PERI-URETHRAL FIBROSIS (PUF), A POSSIBLE ALTERNATIVE SOURCE OF LUTS (2020) (0)
839Results from the mtops study — Outcomes and the AUA symptom score (2005) (0)
Preoperative Multiparametric Prostate Magnetic Resonance Imaging Structured Report Informs Risk for Positive Apical Surgical Margins During Radical Prostatectomy (2022) (0)
1095 Nocturia improvement in the combination of Avodart® and Tamsulosin (CombAT) study (2013) (0)
PD64-02 REAL LIFE EXPERIENCE WITH THE REZUM SYSTEM FOR BENIGN PROSTATIC HYPERPLASIA (2018) (0)
1385 EFFECTS OF FINASTERIDE AND TADALAFIL COMBINATION THERAPY ON LOWER URINARY TRACT SYMPTOMS AND ERECTILE FUNCTION IN MEN WITH PROSTATIC ENLARGEMENT: A RANDOMIZED, PLACEBO-CONTROLLED 6-MONTH STUDY (2013) (0)
A new risk calculator to predict changes in IPSS score and risk of AUR / BPH-related surgery in BPH patients with moderate-severe symptoms at risk of disease progression receiving placebo, dutasteride, tamsulosin, or combination therapy (2021) (0)
MP13-18 GLEASON GRADE GROUP CONCORDANCE BETWEEN PREOPERATIVE TARGETED BIOPSY AND RADICAL PROSTATECTOMY (2020) (0)
POD-04.06 The Effect of Increasing Doses of a Saw Palmetto Fruit Extract on Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Randomized Trial (2011) (0)
Outcomes of early vs. delayed combination medical therapy in LUTS/BPH patients with moderate to severe symptoms: Results from clinical trial simulations using individual IPSS trajectories (2019) (0)
5-alpha-Reductase Inhibitors Prevent the Progression of Benign Prostatic Hyperplasia. (2003) (0)
1644: A Comparison of Men with a Four Point Increase - Confirmed or Not Confirmed in the AUA Symptom Score - Results from the MTOPS Study (2005) (0)
09 Construct validity of the biometric smoothness in the PROMIS system: impact evaluation in a urology training program Early after radical prostatectomy for prostate PROGRAMME SCIENTIFIQUE SCIENTIFIC PROGRAM le 9 Session scientifique I (2007) (0)
Incorporation and adaptation of intestinal segments into the urinary tract (2007) (0)
284Prostate specific antigen (PSA) and post void residual (PVR) urine volume predict relapse of urinary retention and need for surgery in patients with benign prostatc hyperplasia (BPH) after a first episode of acute urinary retention (AUR) (2005) (0)
MP-13.13 Robotic Assisted Laparoscopic Prostatectomy (RALP): Functional Outcomes and Learning Curve (2011) (0)
MP-06.17: Efficacy and safety of dutasteride, tamsulosin and the combination in Asian men: 4-year results from the randomised, double-blind, CombAT trial (2009) (0)
1430: Induction of Smooth Muscle Myogenic Expression in BPH Stroma Cell in Culture (2005) (0)
A Preliminary Study of JM-27: A Serum Marker That Can Specifically Identify Men With Symptomatic Benign Prostatic Hyperplasia (2007) (0)
PD47-12 DIAGNOSTIC PERFORMANCE OF PROSPECTIVELY ASSIGNED LIKERT SCALE SCORES FOR DETERMINATION OF EXTRAPROSTATIC TUMOR EXTENSION WITH MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING OF THE PROSTATE (2018) (0)
Quick improvement of urinary symptoms of benign prostatic hyperplasia with silodosin (Rapaflo) (2009) (0)
908 ASSOCIATION OF BLOOD LEVELS OF UROKINASE PLASMINOGEN ACTIVATOR AND ITS SOLUBLE RECEPTOR WITH PROSTATE CANCER PRESENCE, INVASION, PROGRESSION, AND METASTASIS (2007) (0)
Self-assessed Health, Sadness and Happiness in Relation to the Total Burden of Symptoms From the Lower Urinary Tract (2006) (0)
Platinum Priority – Benign Prostatic Hyperplasia (2016) (0)
Men’s Sexual Health Questionnaire score changes vs spontaneous sexual adverse event reporting in men treated with dutasteride/tamsulosin combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A post hoc analysis of a prospective, randomised, placebo‐controlle (2020) (0)
Special Issue: Current practices in the management of benign prostatic hyperplasia. Introduction. (2008) (0)
Urodynamics after TURP and HoLEP in urodynamically obstructed patients: Are there any differences at 1 year of follow-up?: Rigatti L, Naspro R, Salonia A, et al (Univ “Vita-Salute,” Milan, Italy) Urology 67:1193–1198, 2006 § (2007) (0)
Collaborative Review - Sexual Medicine - LUTS Critical Analysis of the Relationship Between Sexual Dysfunctions and Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (2011) (0)
068 Prostatic Urethral Lift Preserves Sexual Function: 4 Year Results from LIFT Randomized Study (2017) (0)
The WATER study clinical results – a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate-to-severe LUTS in men with BPH (2018) (0)
1794: Verification Bias in the Assessment of Prostate Specific Antigen (PSA) As a Screening Test for Prostate Cancer (2004) (0)
Natural History of Progression After Biochemical Failure Following Postoperative Radiation Therapy in Prostate Cancer (2016) (0)
The Impact of BPH Care: Procedural complications associated with MIST and traditional surgery compared to disease progression with medical therapy (2023) (0)
PD23-04 ADDED VALUE OF SYSTEMATIC BIOPSIES IN MEN WITH ABNORMAL MULTIPARAMETRIC MRI UNDERGOING MRI-TRUS FUSION PROSTATE BIOPSY (2018) (0)
PD39-11 PEAK URINE FLOW PREDICTS DEVELOPMENT OF SYMPTOMATIC BPH IN MEN WITH MILD TO NO URINARY SYMPTOMS: RESULTS FROM REDUCE (2015) (0)
Holmium Laser Enucleation of the Prostate Versus Open Prostatectomy for Prostates > 70 g: 24-Month Follow-up: Naspro R, Suardi N, Salonia A, et al (Univ “Vita-Salute,” Milan, Italy) Eur Urol 50:563–568, 2006 § (2007) (0)
Prostatic Urethral Lift for Obstructive Median Lobes: Consistent Results Across Controlled Trial and Real-World Settings (2022) (0)
META-ANALYSIS OF TWO-YEAR, PLACEBO-CONTROLLED CLINICAL TRIAL DATA OF FINASTERIDE (1999) (0)
Five-year preliminary functional urinary outcomes of the prospective, randomized controlled trial of convective water vapor thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia (2020) (0)
In reply [7] (2007) (0)
SERUM PROSTATE-SPECIFIC ANTIGEN AS A BIOMARKER FOR DISEASE PROGRESSION IN BENIGN PROSTATIC HYPERPLASIA * (2003) (0)
Corrigendum to: "The Influence of Baseline Parameters on Changes in IPSS with Dutasteride, Tamsulosin, and Combination Therapy: Two-Year Data from the Combination of Avodart® and Tamsulosin (CombAT) Study" [Eur Urol Suppl 2008;7:171 (Abstract no. 403)]. (2009) (0)
Castration-Insensitive Luminal Cells of the Proximal Prostate are Urethral in Origin (2020) (0)
Management of male lower urinary tract symptoms: ability to correctly identify and consequences of incorrect consumer decision (2015) (0)
MP13-07 AQUABLATION THERAPY® VS TRANSURETHRAL RESECTION OF THE PROSTATE: 5-YEAR OUTCOMES OF THE WATER RANDOMIZED CLINICAL TRIAL FOR MEDIUM-SIZED PROSTATES (2023) (0)
MP-13.12 Robotic Assisted Laparoscopic Prostatectomy (RALP): Perioperative Complications and Oncological Outcomes (2011) (0)
Characteristics of men with untreated LUTS interested in over-the-counter tamsulosin. (2019) (0)
287Value of the transition zone index in predicting changes in symptoms and maximum flow rate and risk of acute urinary retention and BPH-related surgery in men with symptomatic BPH (2005) (0)
Outcomes in patients with high-risk prostate cancer treated with definitive versus adjuvant radiation therapy. (2016) (0)
MP-09.18 : Use of alternative therapies by men enrolled in the USA BPH Registry & Patient Survey (2006) (0)
Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy in LUTS/BPH patients with moderate-severe symptoms at risk of disease progression: Results from clinical trial simulations using risk of AUR or BPH-related surgery (2020) (0)
Four year results of water vapor thermal therapy for treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH): What minimal important difference (MID) in symptom relief benefits patient quality of life? (2019) (0)
An alternative model for the management of lower urinary tract symptoms presumed to be due to benign prostatic hyperplasia (2015) (0)
LONGITUDINAL FOLLOW-UP OF SERUM PROSTATE SPECIFIC ANTIGEN (PSA) LEVELS FOLLOWING TRANSURETHRAL RESECTION OF THE PROSTATE (TURP) FOR BENIGN PROSTATIC HYPERPLASIA (BPH) (1999) (0)
Pooled outcomes from five Prostatic Urethral Lift (PUL) controlled studies reveal most patients can shift to lower IPSS symptom severity after treatment (2022) (0)
LUTS: In many cases, men may not be suffering alone (2001) (0)
Introduction (2008) (0)
Target Issue: Body in Cyberspace /whois? Identity: Collectivity and the Self in Irc…………………………………….pag. 87 Display Techniques and Methods for Cross-medial Data Analysis…………….……pag.131 Optimization of Computer Presented Information for Left-handed……………………pag.151 Observers Testing Driver's Comfort in V (0)
1122: Molecular Characterization of Epithelial to Mesenchymal Transition in Human Prostatic Epithelial Cells (2007) (0)
MP58-18 A COMPARISON OF PATIENT COMFORT AND SATISFACTION AFTER ROBOTIC PROSTATECTOMY WITH SUPRAPUBIC TUBE VERSUS URETHRAL CATHETER DRAINAGE (2014) (0)
Reply (2003) (0)
UP-02.160 Prognostic Value of Insulin-like Growth Factor II mRNA Binding Protein 3 (IMP3) in Prostate Cancer (2011) (0)
The appropriate evaluation of the benign prostatic hyperplasia patient (1994) (0)
Mapping the Treatment Journey for Patients with Prostate Cancer (2018) (0)
Long-Term Outcome of Prostate Cancer Patients Who Fail Salvage Radiation Therapy and Radical Prostatectomy (2014) (0)
Transurethral microwave thermotherapy effectiveness in small prostates (2007) (0)
5-YEAR RESULTS OF A MULTI-CENTER STUDY OF COOLED THERMOTHERAPY FOR BENIGN PROSTATIC HYPERPLASIA (2009) (0)
1699: The Observed Effect of Flomax Intake on Sexual Health in Men with Lower Urinary Tract Symptoms. Analysis from the Prostate Cancer Awareness Week (PCAW) (2005) (0)
Alfuzosin 10 mg Once Daily in the Management of Acute Urinary Retention: Results of a Double-blind Placebo-controlled Study: McNeill SA, for the Alfaur Study Group (Western Gen Hosp, Edinburgh, England; et al) Urology 65:83–90, 2005 § (2006) (0)
Aquablation Therapy in Large Prostates (80-150 mL) for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Final WATER II 5-Year Clinical Trial Results. (2023) (0)
MP-05.17 The Prostatic Urethral Lift: A New, Minimally Invasive Therapy for BPH (2011) (0)
Issue Information (2021) (0)
Discussion following Dr. Blute'S presentation (2001) (0)
MP28-19 A NEW RISK CALCULATOR TO PREDICT CHANGES IN INTERNATIONAL PROSTATE SYMPTOM SCORE AND RISK OF RETENTION OR SURGERY IN BENIGN PROSTATIC HYPERPLASIA PATIENTS WITH MODERATE-SEVERE SYMPTOMS AT RISK OF DISEASE PROGRESSION RECEIVING PLACEBO, DUTASTERIDE, TAMSULOSIN, OR COMBINATION THERAPY (2021) (0)
Management of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia With Open Prostatectomy: Results of a Contemporary Series (2007) (0)
Characterization of the response of symptomatic benign prostatic hyperplasia (BPH) to terazosin by prostate size (1997) (0)
AUTHOR REPLY. (2019) (0)
PD18-08 PRESERVATION OF SEXUAL FUNCTION 5-YEARS AFTER WATER VAPOR THERMAL THERAPY FOR BENIGN PROSTATIC HYPERPLASIA (2021) (0)
The Association Between Lower Urinary Tract Symptoms and Renal Function in Men: A Cross-Sectional and 5-Year Longitudinal Analysis: Ponholzer A, Temml C, Obermayr RP, et al (City Of Vienna, Austria) J Urol 175:1398–1402, 2006 § (2007) (0)
Introduction (2006) (0)
Benign prostatic hyperplasia. (2019) (0)
EFFECT OF PHOSPHODIESTERASE TYPE 5 INHIBITOR (PDE5I) USE ON LOWER URINARY TRACT SYMPTOMS (LUTS) OVER TIME AMONG MEN ON WATCHFUL WAITING VERSUS BPH MEDICAL THERAPY: RESULTS FROM THE BPH REGISTRY (2009) (0)
280 WHAT PROPORTION OF PATIENTS' SATISFACTION WITH TREATMENT IS EXPLAINED BY CHANGES IN COMONLY USED LUTS/BPH ASSESSMENT PARAMETERS? (2009) (0)
BJU International, Supplement: Introduction (2008) (0)
1578: BMI and its Ability to Improve Prediction of Biochemical Recurrence (BCR) after Radical Prostatectomy (RP): Does a Statistically Significant Marker Always Improve Predictive Accuracy in Multivariate Models? (2006) (0)
Issue Information (2019) (0)
1361: A Modified American Urological Association (AUA) Symptom Score (2006) (0)
Biopsy, Diagnosis, and Staging of Prostate Cancer (2009) (0)
BJU International: Introduction (2008) (0)
A Randomised, Placebo-Controlled Study to Assess the Efficacy of Twice-Daily Vardenafil in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Stief CG, Porst H, Neuser D, et al (Ludwig-Maximilians-Univ, Munich, Germany; Private Urological Practice, Hamburg, Germ (2008) (0)
Molecular Characterization of Epithelial to Mesenchymal Transition in Human Prostatic Epithelial Cells (2010) (0)
1703: Transition Zone Hypothesis in Benign Prostatic Hyperplasia (2005) (0)
A real world single office experience with the Rezum radio frequency water vapor thermal therapy system for benign prostatic hyperplasia (2018) (0)
PD04-06 ARTIFICIAL URINARY SPHINCTER REVERSES WEIGHT GAIN ASSOCIATED WITH POST-PROSTATECTOMY INCONTINENCE (2021) (0)
Book Review Prostate Cancer (American Cancer Society Atlas of Clinical Oncology.) Edited by Peter R. Carroll and Gary D. Grossfeld. 402 pp., illustrated, with CD-ROM. Hamilton, Ont., Canada, BC Decker, 2002. $159. 1-55009-130-1 (2002) (0)
MP45-09 PROSTATE VOLUME DOES NOT SIGNIFICANTLY AFFECT THE RISK OF POST-SURGICAL COMPLICATIONS AFTER ROBOT-ASSISTED SIMPLE PROSTATECTOMY (2019) (0)
Androgen Deprivation Therapy for Prostate Cancer: Specialty Clinic Collaboration and the Electronic Medical Record Can Improve Bone Health Monitoring (2020) (0)
MP57-09 PROXIMITY OF POSITIVE PROSTATE BIOPSY CORE TO CAPSULAR MARGIN MAY HELP PREDICT EXTRACAPSULAR EXTENSION AND POSITIVE MARGIN AT PROSTATECTOMY (2016) (0)
The UroLift implant: mechanism behind rapid and durable relief from prostatic obstruction (2021) (0)
IMPROVEMENTS IN SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA AND RELATED QUALITY OF LIFE FOR MEN WITH OR WITHOUT ERECTILE DYSFUNCTION TREATED WITH ONCE DAILY TADALAFIL (2009) (0)
DOES TREATING NOCTURIA LEAD TO BETTER SLEEP? RESULTS FROM REDUCE: MP13‐13 (2017) (0)
Dose-Intensified Stereotactic Ablative Radiation for Localized Prostate Cancer (2022) (0)
Perception of benign prostatic hyperplasia (BPH): Cultural differences in symptoms and impact (1997) (0)
437 MULTI-CENTER STUDY OF THE PROSTATIC URETHRAL LIFT: A MINIMALLY INVASIVE ALTERNATIVE FOR BPH (2011) (0)
Over-the-Counter Tamsulosin for Men with Urinary Symptoms: A Simulated Self-Selection Study (2020) (0)
PD10-07 MULTI-INSTITUTIONAL PROPENSITY MATCHED COMPARISON OF ROBOTIC-ASSISTED SIMPLE PROSTATECTOMY AND THULIUM LASER ENUCLEATION OF THE PROSTATE (2019) (0)
PD39-02 ESTROGEN, BUT NOT TESTOSTERONE, IS ASSOCIATED WITH LOWER URINARY TRACT SYMPTOMS AT BASELINE AND FOLLOWING TREATMENT WITH TADALAFIL: ANALYSIS OF POOLED CLINICAL TRIALS DATA. (2015) (0)
A NEW VISUAL POINT-OF-CONTACT PSA TEST: RESULTS OF A PILOT STUDY (1999) (0)
RACE SPECIFIC DIFFERENCES IN HISTOPATHOLOGY OF PROSTATE CANCER IN AN EQUAL ACCESS HEALTH CARE SYSTEM (1999) (0)
Calculation of quasi-IPSS index. Authors' reply (1997) (0)
LOW TESTOSTERONE LEVELS PREDISPOSE TO URETHRAL ATROPHY DUE TO DECREASED URETHRAL VASCULARITY VIA AN ANDROGEN RECEPTOR‐MEDIATED PROCESS: MP36‐03 (2017) (0)
Prospective Monitoring and Adapting Strategies for Prevention of Infection Following Transrectal Prostate Procedures (2017) (0)
MP04-08 CHARACTERISTICS OF MEN WITH UNTREATED LOWER URINARY TRACT SYMPTOMS PARTICIPATING IN A STUDY ASSESSING SELF-DIRECTED USE OF OVER-THE-COUNTER TAMSULOSIN (2018) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Claus Goerg Roehrborn?

Claus Goerg Roehrborn is affiliated with the following schools:

Queen's University at Kingston
University of Texas at Dallas
University of Virginia
Baylor University
University of Texas Southwestern Medical Center